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Enhancing the effectiveness of medical device incident reporting 
Use of globally harmonised nomenclature for adverse event reporting of medical devices is a key prerequisite for 
effective safety monitoring of devices in the interest of patient protection. This report analyses the results of an 
EU pilot project on nomenclature use and makes recommendations. 
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1 
Executive summary 
 
Aim of the report 
This report provides a final assessment by DG JRC of the 'EU MIR form pilot' project, 
concerning the use of nomenclature for manufacturer incident reporting. The purpose of 
this analysis is to exploit the submitted data in view of addressing the following key 
questions:  
1. Is reporting of adverse events using nomenclature feasible and helpful? 
2. Are existing nomenclatures relating to device problems and evaluations of causes 
adequate? 
3. Is there a need for introducing new terms, e.g. to cover novel technologies? 
4. What are the lessons learned from the pilot study in terms of international 
harmonisation of nomenclatures (IMDRF) and development of future reporting 
tools (e.g. EUDAMED)? 
Key findings  
This report focuses on the use of adverse 'event-type' and 'evaluation' terms which 
relate to problems with the medical device. The device-related terms were used in a 
'Manufacturer Incident Report' form, which was designed for the pilot study, and was 
called the MIR pilot form. 786 forms, which were submitted by 13 manufacturers 
reporting from 15 European countries, were analysed. 
Concerning nomenclature usage, the report analyses whether incidents were reported 
adequately using (1) existing nomenclature (ISO/TS 19218), (2) newly introduced 
nomenclature (EDMA's IVD-related terms), and (3) newly proposed terms (by the 
participating manufacturers of the pilot study).  
The analysis has shown a number of important issues which concern five main topics: 
 
1. Pilot data relate to approx. 50% of device categories on the market 
Due to voluntary participation, the submitted MIR pilot forms reflect only a certain 
proportion of medical devices on the market. This needs to be considered when 
interpreting and using the pilot data.  
 
2. No participation of SMEs in the pilot project 
Additional bias may be due to (1) the absence of SME participation; and (2) a single 
manufacturer submitting >60% of the total number of forms (bias towards a 
particular device category). 
 
3. Adequacy of term selection by manufacturers 
We assessed the adequacy of term use by comparing textual incident descriptions 
with the categorised terms chosen by reporters. It was based on a set of 100 
randomly selected pilot forms representative of the pilot's overall device portfolio. 
Both, the event-type and evaluation terms chosen by manufacturers for reporting 
incidents were largely adequate. 
 
Moreover, the analysis shows that three choices per level to describe the incident 
(event-type terms) or final investigation (evaluation terms) appear sufficient.  
 
4. Available terminology (ISO/TS 19218) is not fully adequate 
On the basis of the frequency of some proposed terms it appears that the existing 
ISO/TS 19218 terms are overall not sufficient. This is not surprising given the fact 
that the terms were derived from FDA's terminology in 2005 and have, since then, 
not been updated. To resolve the most frequently encountered issues in the analysis, 
the JRC has proposed several changes to terms used (cf. Fig. 18-24). 
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5. Proposals for new terms by manufacturers 
ISO/TS 19218 uses a 2-level hierarchical coding structure for reporting adverse 
events. Though the pilot study allowed for new proposals at these levels (level 1, 2), 
it was particularly designed for new proposals at an additional more granular third 
level. In line with this is the observation that the majority of new terms proposed 
concern level three terms. 
 
The analysis also showed that, although selection of existing terms was overall 
adequate, many of the new terms proposed by manufacturers are either redundant or 
do not reflect device problems but are, in fact, patient outcome terms. This clearly 
shows a need for reporters to have a better understanding of the terms and the 
reporting form used. Some of the confusion may stem from the simple fact that ISO's 
medical device problem terminology is called "Adverse Event Terms", i.e. seemingly 
suggesting that this nomenclature should be used to report adversity, i.e. clinical 
phenomena at patient / user level.  
 
In cases where level one event-type terms have been proposed, these related mainly 
(>80%) to the orthopaedic device category (cf. Fig. 13). It therefore appears that 
there is a need for a more elaborate nomenclature in this device category.  
 
Proposed terms that were deemed valid when compared with ISO/TS 19218 were 
subsequently compared with FDA's terms for device problems. This led to the 
identification of a number of proposed terms that could be proposed for incorporation 
into ongoing efforts in the development of a globally used nomenclature in the 
context of the work of the Adverse Event Terminology Working Group of IMDRF. 
 
EDMA has proposed new terms to cover specific needs of reporting incidents with in 
vitro diagnostic medical devices (IVDs). These were meant to complement the ISO/TS 
19218 terms, and several of them have been used in the submissions. A closer look 
at the definitions of some of EDMA's terms does, however, show that they would need 
to be revised, for example four terms (corresponding to level 2) have identical 
definitions adding unnecessary ambiguity to their use. 
 
The report also provides in Annex I a summary of agreements reached during the 
workshop and topics that remain to be addressed when developing future tools for 
incident reporting including concerns voiced by stakeholders. Annex I also considers 
additional reflections made after the workshop and provides, as a synthesis, key 
recommendations for a way forward. 
 
In summary, this report shows that the outcome of the 'EU MIR form pilot' project has 
proven to be extremely useful for three reasons. 
1. It confirmed the general feasibility of categorised reporting of incidents by 
manufacturers. 
2. It identified inadequacies of the existing ISO/TS 19218 nomenclature suggesting 
the need for increased efforts into the development of freely available, 
scientifically and technically satisfying and, from a regulatory and end-user point 
of view, adequate nomenclature for adverse event reporting of incidents and 
events also in the pre-market space. 
3. It led to the proposal of several potentially useful terms in view of future 
developments of nomenclature for incident / adverse event reporting.  
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1 Introduction 
 
This document provides the final assessment by JRC on nomenclature used in the 'EU 
MIR form pilot' project. The pilot project was launched in the framework of the Vigilance 
MDEG activity to explore the use of predefined nomenclature for incident 
reporting of medical devices. This is a prerequisite for a more effective monitoring in 
the future of the safety of devices on the market through signal detection and trend 
analysis.   
The MHRA and the European Commission (DG GROW, DG JRC) devised and ran the 
project. It started on 1 May 2015 and ran for 9 months until 3 February 2016, coinciding 
with a workshop entitled: 'Developing a roadmap for the integrated MIR form' organised 
by the European Commission (DG GROW, DG JRC) and MHRA, and hosted by COCIR.  
A first interim report, which analysed a smaller data set corresponding to the first 4 
months of the pilot project was issued on 30 November 2015, while a second more 
elaborate interim report was issued on 7 April 2016 and analysed data acquired over 
7 months of the project. During the pilot project, an evident delay of forms arriving at 
the single collection point at DG SANTE was observed, and to compensate for this, we 
concluded that the analysis for the final report would be based on forms submitted two 
months after the end of the project (1 April 2016).  
In total, 786 forms, which were submitted by 13 manufacturers reporting from 
15 European countries, were analysed. Because a substantial and in-depth analysis 
of event-type and evaluation terms had already been carried out in the second interim 
report (based on 415 forms), and since there were no marked differences in the type of 
incidents being reported in the forms that followed, the relevant parts of this report are 
based on earlier analyses. 
While the pilot project also allowed the use of available patient problem terms (e.g. 
MedDRA, SNOMED-CT, ICD 10, FDA), only a small fraction of submitted incident reports 
contained patient problem terms. The report hence focuses on use of adverse 'event-
type' and 'evaluation' terms, which relate to problems with the medical device.  
The insights gained from this assessment will:  
(1) support the creation of a novel MIR form containing both provisions for textual and 
categorised reporting using nomenclatures;  
(2) inform the development of an outline ("blueprint") for a future fully electronic 
incident report template to be designed in the context of the new European database 
on Medical Devices (EUDAMED); and  
(3) provide input to current efforts in the international harmonisation of adverse 
event and evaluation terms (International Medical Device Regulators Forum, IMDRF), 
activities that are strongly supported by EU. 
  
  
 
4 
2 Background and aim 
 
In view of an effective implementation of the new medical device regulation within the 
EU, the Commission has opted for a co-management of the regulatory framework 
involving DG GROW (policy lead) and DG JRC (scientific and technical aspects). To 
realise this, the JRC has built up capacities at Directorate F. 'Health, Consumers and 
Reference Materials' in Ispra, Italy that will provide scientific and technical support to 
this process.  
 
One of the main areas of activity, which has been defined in the framework of co-
operation between DG GROW and DG JRC (i.e. the so-called 'Administrative 
Arrangement') is the area of vigilance/market surveillance (AIRN-MD II project on ‘Post 
Market Safety - Medical Devices (MDs) and In Vitro Diagnostic Medical Devices (IVDs)’;   
contract no. 33983). Focus areas include the analysis of incident reporting for medical 
devices relevant for the European market. The overarching aim is to contribute to the 
development of an effective EU vigilance system allowing for effective signal detection 
and trend analysis in incident reporting, thereby permitting rapid corrective response.  
 
A key prerequisite for an effective analysis of incident data on medical device problems, 
and possible adverse events encountered as a consequence, is the use of structured, 
categorised data based on standardised nomenclatures and coding systems that allow 
capturing incidents/adverse events through pre-defined keywords (terms).  
 
Without structured data, signal detection and trend analysis will be limited to a purely 
qualitative evaluation of reports and report clusters that need to be, in a rather laborious 
manner, analysed and grouped by Competent Authorities (CAs), including insertion in 
existing national databases.  
 
Thus, the introduction of the mandatory use of nomenclatures by manufacturers for 
reporting medical device problems, evaluations into causes and adversity at patient/user 
level would greatly enhance data monitoring, querying, visualisation and overall 
analysis, facilitating signal detection on the basis of single reports or clustered data 
alike. Moreover, if such data structure/nomenclatures were introduced at EU level, it 
would give MS CAs a powerful tool (e.g. EUDAMED) for cooperating on medical device 
management across the single European market.  
The pilot project is part of ongoing endeavours by CAs and Commission (DG GROW/JRC) 
to construct effective EU-level means of post-market reporting of incidents, serious 
incidents and adverse events. Notably, nomenclatures for post-market purposes could be 
equally used for pre-market reporting of Adverse Events and Serious Adverse Events 
encountered in the context of clinical trials.  
The present analysis of the use of adverse 'event type' and 'evaluation' terms (ISO 
19218) used by manufacturers in the context of this pilot, exploits these data in view of 
identifying the adequacy of existing terminology (ISO/TS 19218), the relevance and 
necessity of newly proposed terms and thus will inform future work towards 
development of a novel MIR form incorporating nomenclature use as well as future tools 
(e.g. EUDAMED) for incident reporting. The analysis made use of the "MIR additional 
information form" developed for the MIR pilot and allowing nomenclature use, but also of 
the existing MIR form that provides textual / narrative descriptions of incidents. The 
insights gained from this analysis will not only be relevant for the move to a more 
effective and fully operational EU vigilance system, but it will also provide valuable 
contribution to the international harmonisation of adverse event terms (International 
Medical Device Regulators Forum, IMDRF).  
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3 Method for assessing nomenclature 
 
To carry out this analysis, the MHRA (Medicines & Healthcare products Regulatory 
Agency, UK) together with the European Commission has set up an 'EU MIR form pilot' 
with a collection point at DG SANTE and a specifically designed manufacturer incident 
report (MIR) form, the MIR additional information form (MIR pilot form). This form 
complements the current way that manufacturers report on incidents. The MIR pilot form 
pdf document is available at:  
http://ec.europa.eu/growth/sectors/medical-devices/guidance/index_en.htm 
(see: Guidance MEDDEVs/ 2.12 Market Surveillance/ EU Vigilance Pilot on Trending). It 
consists of various sections one of which is relevant for incident information (event type 
codes/terms) and another for the manufacturer's final investigation (evaluation 
codes/terms). In addition to predefined terms (in pull-down menus), free-text fields also 
exist allowing new (event type or evaluation) terms to be proposed for incident 
reporting. The terms used to describe incidents are categorised in two levels (level 1,2) 
with one being more detailed than the other. It is possible for manufacturers to propose 
an extra level of detail (level 3) to describe the incident or to propose new level 1 or 2 
terms. More specifically, this logical tree of three branch levels allows for these three 
term use/ proposal scenarios, of which only the first is evident and user friendly: 
 
1. The manufacturer can choose appropriate level 1 and 2 terms from the existing 
ISO/TS 19218 catalogue or from EDMA's newly proposed terms. However, to add 
more resolution/granularity, the manufacturer can suggest an additional third 
level term, branching off the respective level 2 term. This is in line with the 
current design of the MIR pilot form (dedicated space for 'Manufacturer event-
type level 3 code', and similarly for 'Manufacturer evaluation level 3 code') 
 
2. The manufacturer can choose an appropriate level 1 description, but if there is no 
appropriate associated level 2 description/ term, the manufacturer must do the 
following (user-unfriendly) procedure to suggest a new second level term: after 
choosing any of the available second level terms (pull-down menu) and 
subsequently entering the proposal for a new second level term in the free-text 
space dedicated for level 3 term, only then can the chosen (pull-down menu) 
second level term be changed back to 'unselect'. 
 
3. The manufacturer can not find an appropriate level 1 term and chooses the 
category 'other' (e.g. code 2300 'An event type not otherwise included in this 
table resulting in a device related event'). Subsequently 'Other' is chosen again at 
level 2, and a new first level term is proposed in the space dedicated for level 3 
proposals. 
 
Box 1. Links to the terms, codes, and definitions used in the 'EU MIR form pilot'. 
ISO/TS 19218 (part 1, 2) terms can be found via: 
http://www.iso.org/iso/home/store/catalogue_tc/catalogue_tc_browse.htm?commid=54892 
EDMA's IVD-related terms can be found via:  
http://ec.europa.eu/growth/sectors/medical-devices/guidance/index_en.htm  
(see: Guidance MEDDEVs/ 2.12 Market Surveillance/ EU Vigilance Pilot Toolkit for Users/ 
documents 7 and 8) 
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The method used to evaluate the new terms (EDMA's IVD-related terms), as well as the 
newly proposed (level 1, 2 and 3) terms was as follows: 
 
1. Eligibility of submitted data 
a. Completeness check of the submitted MIR additional information form (MIR 
pilot form, xml format).  
2. Adequacy of used terms  
a. A random set of 100 representative submitted pilot forms were analysed for 
the adequacy of terms selected by manufacturers for incident reporting. The 
evaluation consisted of a comparison of these terms with the descriptive text 
of the incident and the manufacturer's final investigation found within the 
(MEDDEV) MIR form.   
3. Analysis of proposed terms 
a. Use frequency:  
Frequently proposed terms of the same type could indicate a systemic 
problem to describe the incident or it could reflect an often occurring event 
that is not described within the existing terms. The use frequency will need to 
be weighted relative to the number of manufacturers proposing the same/ 
similar term, with more weight being assigned if more manufacturers propose 
the term. At this point, with 786 submitted forms, the relatively low sample 
number does not allow for deep statistical analysis.  
b. Resolution/ hierarchical level:  
Does the proposed term match the proposed level (1, 2 or 3), in other words: 
is the hierarchical level adequate? 
e.g. for event-type terms: 
 Level 1: broadly defining the property of the device that the failure was 
observed to affect 
 Level 2: how the failure affected the properties of the device 
 Level 3: how the adverse event was observed to have occurred 
c. Overlap with already existing terms: 
Do already existing terms sufficiently describe what the newly proposed term 
describes? This could possibly be the result of a report being filled in by a 
reporter with insufficient knowledge of the existing codes. 
 No overlap: the term could be considered for addition to ISO/TS 19218-
1&2 or more relevantly (if not present within FDA's device problem terms) 
for addition to the nomenclature intended for global use that is currently 
being developed by IMDRF (and is based on FDA's terms).   
 Overlap: 
i. Redundant if equivalent terms exist 
ii. Possibly request for change of existing terms (ISO/TS 19218-1&2, 
IMDRF nomenclature) if the proposed term is evaluated as better 
d. Definition:  
i. Is the proposed definition/description sufficiently detailed or described 
broadly enough? This would be a requirement for the development of 
clear and useful nomenclature. 
4. Cross-check of analysis by another evaluator within JRC's Medical Device 
Task Force 
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4 Results of the assessment 
 
4.1 Eligibility check and analysis of number of proposed terms 
 
This analysis is based on 786 MIR pilot forms that DG SANTE received on 1 April 2016. 
This corresponds with a period of (1) the full 9 months of the pilot, which started on 1 
May, 2015, and (2) two additional months to compensate for the delay observed in 
forms arriving at the collection point. The eligibility check of the MIR pilot forms resulted 
in the elimination of 45 submissions (5.7%) due to lack of sufficient, essential 
information needed to identify either the manufacturer or the device (Table 1). Of the 
remaining 741 eligible submissions, 718 (96.9%) contained proposals for new 'event-
type' terms or used one of EDMA's newly introduced 'event-type' terms (Table1, Fig. 1). 
For evaluation terms, 549 (74.1%) submissions contained proposals for new terms and 
there were no submissions with EDMA's newly introduced evaluation terms (Table 1, Fig. 
2). 
 
Table 1. Number and percentage of eligible submitted MIR pilot forms with/without proposals for new 'event-
type' and 'evaluation' terms. n/a: not applicable; total number of forms = 786 (741 eligible + 45 non-eligible); 
Indicated percentages reflect only eligible forms; Values are based on the first entry (choice) of terms which 
were the predominantly chosen ones (see Table 5; Fig.7,8). 
 
Eligible submitted MIR pilot forms 
(total: 741) 
Non-eligible 
submitted MIR 
pilot forms 
(total: 45) 
 
With proposals 
for new terms 
With EDMA's 
new terms 
Without proposals 
for new terms 
 
Event-type terms 654 (88.3%) 64 (8.6%) 23 (3.1%) n/a 
Evaluation terms 549 (74.1%) 0 192 (25.9%) n/a 
 
 
 
Figure 1. Percentage of eligible submitted MIR pilot forms with/ without proposals for new 'event-type' terms 
and with EDMA's new 'event-type' terms. Values are based on Table 1. 
 
 
88.3% 
8.6% 
3.1% 
with proposals for new terms
with EDMA's new terms
without proposals for new
terms
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Figure 2. Percentage of eligible submitted MIR pilot forms with/ without proposals for new 'evaluation' terms 
and with EDMA's new 'evaluation' terms. Values are based on Table 1. 
 
 
 
4.2 Medical device representation within the MIR form pilot 
 
As a brief background, and as described in the 'Q&A document within the 'EU Vigilance 
Pilot Toolkit for Users', Competent Authorities had at the onset of the pilot suggested a 
potential focused participation where all companies in specific sectors would be 
encouraged to participate. The requested device types were: (1) cardiac rhythm 
management implants (e.g. pacemakers and leads); (2) infusion pumps; (3) blood 
glucose meters; (4) surgical staplers; (5) vaginal tapes and meshes; (6) lasers for eye 
surgery; (7) external defibrillators; and (8) annex II list A and list B products. The 
participating manufacturers were also encouraged to choose product areas of high 
volume if they did not wish to participate with their entire product range. 
 
A key issue of the MIR pilot is the representativeness of devices in the pilot relative to 
the market. Bias could be introduced in this way and this needs to be considered in the 
interpretation of the results. There are in fact two relevant aspects to consider: (1) 
representativeness of devices in relation to market coverage; and (2) representativeness 
of different kinds of device manufacturers (i.e. large industries vs small and medium-
sized enterprises (SMEs)). Concerning the latter, no SMEs participated in the pilot. 
Concerning the former, we searched for different ways of categorising medical devices, 
and chose to follow the device classification panels developed by FDA, which is based on 
medical specialities and appeared accessible for the specific purposes of the pilot (Table 
2). Using these panels, we observed 50% coverage of the categories by device types, 
which were requested by competent authorities (CAs).  
In reality, the manufacturers submitted MIR pilot forms to the collection point that to a 
certain extent differed from the device types requested by CAs. In this way several 
different categories were covered, and out of the 741 eligible MIR pilot forms that 
were effectively submitted to the collection point, there was 50% coverage of 
the categories by device types (Table 2). For our calculations we grouped the first 
three classification panels into an in vitro diagnostic medical device (IVD)-containing 
category, as the FDA classifies IVDs in these panels. The IVD-containing category 
74.1% 
0.0% 
25.9% 
with proposals for new terms
with EDMA's new terms
without proposals for new
terms
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together makes up the category that is predominantly represented (>70%) in the pilot, 
with 'orthopaedic devices' (11%) following thereafter (Figure 3). The reason of the 
disproportionate number of devices in the IVD category is the significant amount of 
submitted forms by a single manufacturer in this field. 
 
Table 2.  Medical devices reported in the submitted MIR pilot forms. Device classification panels and risk levels 
developed by FDA. The number of devices reflect the number of MIR forms submitted and do not necessarily 
represent distinct devices. IVD: in vitro diagnostic medical device 
no. 
FDA's device classification panels 
(based on medical specialities) 
risk 
level 
% 
devices 
 
no. 
devices 
1 Clinical chemistry & clinical toxicology devices together:   
2 Haematology & pathology devices 1, 2,3 76 561 
3 Immunology & microbiology devices    
4 Anaesthesiology devices    
5 Cardiovascular devices 2, 3 5.4 40 
6 Dental devices    
7 Ear, nose, & throat devices    
8 Gastroenterology-urology devices    
9 General & plastic surgery devices    
10 General hospital & personal use devices 2 5.4 40 
11 Neurological devices    
12 Obstetrical & gynaecological devices    
13 Ophthalmic devices 2 0.9 7 
14 Orthopaedic devices 2 11 83 
15 Physical medicine devices    
16 Radiology devices 2 1.3 10 
 
 
 
 
Figure 3. Percentage of devices reported within the indicated device categories. Values are based on Table 2. 
 
  
76.0% 
11.0% 
5.4% 
5.4% 
0.9% 1.3% 
Includes in vitro diagnostic
medical devices
Orthopedic devices
Cardiovascular devices
General hospital &
Personal use devices
Ophthalmic devices
Radiology devices
IVD 
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More specifically, the device types reported within the 8 panels are shown in Table 3. 
 
Table 3.  Medical device types reported in the submitted MIR pilot forms. IVD: in vitro diagnostic medical 
device 
no. 
FDA's device classification panels  
(based on medical specialities) 
Device types 
1 
 
2 
3 
Clinical chemistry & clinical toxicology 
devices 
Haematology & pathology devices 
Immunology & microbiology devices 
- DNA detection/ quantification  
 (nucleic acid amplification systems) 
- Blood testing–antibody based 
 (hepatitis B; IgG/ complement) 
- Insulin pump: glucose sensors 
- Blood glucose meters 
- other immunoassays 
5 Cardiovascular devices - Catheter guide wires 
- Intra-aortic occlusion devices 
- Defibrillators 
- Cardiac ablation catheters 
- Implantable pacemakers 
10 General hospital & personal use devices - Enteral feeding pumps 
- Infusion pumps 
- Intravenous solutions/ medication 
  delivery systems  
13 Ophthalmic devices - Microsurgery devices 
- Implantable lenses 
14 Orthopaedic devices - Prosthesis 
(knee/ hip replacements) 
- interspinous implants 
- plate/ screw/ nail systems 
- craniotomies… 
16 Radiology devices - X-ray systems (angiography) 
- digital radiography systems 
 
 
 
4.3 Adequacy assessment of terms used by reporters 
 
To analyse the adequacy of categorical terms used by manufacturers to capture 
incidents we analysed a random set of 100 submitted pilot forms which proportionally 
represented the different device categories/types (see Table 3 and Figure 3). The 
assessment was done by comparing to which extent the terms chosen reflected the 
narrative descriptive text found in the (MEDDEV) MIR form. More specifically, the 
selected event-type terms (pilot form) were compared with the narrative text on the 
incident (MIR form), and similarly the evaluation terms were compared with the text 
accompanying the results of the manufacturer's final investigation. 
 
The adequacy assessment consisted of a sequential analysis where first the narrative 
text describing the incident with the conventional MIR form was studied. Secondly, the 
JRC assigned event-type level one and level two terms and codes. Thirdly, a comparison 
was made with the terms that the manufacturer selected. Finally, the same procedure 
was followed for evaluation terms and the text on the results of the manufacturer's final 
investigation (Figure 4). 
IVD 
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Figure 4. Procedure followed for the adequacy assessment. 
 
 
The analysis showed that for event-type terms there was a high level of agreement of 
terms with 98% of level one terms matching and 89% of level two terms (Table 4). The 
discrepancies observed at level two were most frequently the result of the terms '1404, 
Power Source issue" and '1402, Circuit Failure' which were used interchangeably. 
Notably, for the orthopaedic device category, the event-type term '2300, Other' was 
used in the majority of cases. This could imply the need for a more elaborate 
nomenclature for describing incidents with these devices. In fact, the level one code 
'1600, Implantable device failure' only has 2 level two terms associated with it ('1601, 
Migration of device or device component' and '1602, Osseo-disintegration issue'). For 
this device category, it is therefore recommended to not only (1) further populate the 
nomenclature with new terms, but also to (2) maintain 'Other' as a valid term due to the 
variety and complexity of incidents with implantable medical devices. 
 
Similarly, for evaluation terms the adequacy analysis showed a good agreement of terms 
with 90% of level one terms matching, and 76% of level two terms (Table 4). The most 
frequent discrepancies were observed with the evaluation terms '26802, No medical 
device failure detected' and '26801, No medical device problem', which were often used 
interchangeably.  
 
 Table 4. Representative samples used for the adequacy assessment. MFR L1: Level 1 term/code reported by the manufacturer; MFR L2: Level 2 term/code reported by the 
manufacturer; JRC L1: Level 1 term/code proposed by JRC; JRC L2: Level 2 term/code proposed by JRC; MD: medical device 
 
ADVERSE EVENT-TYPE TERMS/ CODES 
Case No Text MFR L1 
Agree? 
(Y/N) 
JRC L1 MFR L2 
Agree? 
(Y/N) 
JRC L2 
xxx-67 It is reported that 450ml of [BRANDNAME] feed was hung and 400ml set to be delivered at a rate of 
60ml/hr using the above referenced [MD] Pump into a 4yr old male suffering with Pancreatic 
Dysmotility, Eosinophilic Duodenitis and Ehler-Danlos Syndrome. It is reported that after 
approximately 2 hours the pump was stopped whilst the patient was attended to; at which point 
around 150ml had been delivered as expected. Having restarted the pump for the remainder of the 
overnight feed to be delivered, it was noted the following morning that none of the remaining feed 
was delivered. It is also alleged the pump failed to alarm to indicate an occlusion. 
[1800] 
Infusion/Flow 
Y - [1806] 
Insufficient 
Flow or 
Underinfusi
on 
Y - 
xxx -189 On 07/21/2015, the reporter contacted [MFR], alleging a DISPLAY (DAMAGED) issue with a cracked 
display lens.  There was no health consequence to the patient associated with the reported 
incident, and no medical treatment or health care provider intervention was required. Therefore, 
there is no healthcare provider information to report. 
[2000] 
Material 
Y - [2002] 
Crack 
Y - 
xxx -237 The customer reported that during a Transcatheter Aortic Valve Implantation (TAVI) procedure 
with an anaesthetized patient on the table, that when the table was put into a tilt position, the 
table top became unstable and immediately lurched uncontrolled in the direction of the tilt. The 
staff in the near vicinity managed to stop the patient / table before the patient came to any harm. 
[2100] 
Mechanical 
Y - [2107] 
Unintended 
Movement 
Y - 
xxx -70 The [MD] System is intended for use in performing nucleic acid testing in clinical laboratories. It is 
comprised of the [MD] and [MD] instruments. The [MD] instrument is an automated fluid handling 
system for performing sample preparation for nucleic acid testing. The [MD] System Software is an 
automated system for performing fluorescence-based PCR that results in quantitative and 
qualitative detection of nucleic acid sequences.  A Field Service Specialist (FSS) performed Lamp, 
Lamp Socket/Cable Assembly, Lamp-Gemini Cord with Connector replacement as per ISA 610-028. 
Visual verification showed a brown coloration of the Lamp Socket that required replacement. The 
PCA Microcontroller verification procedure shows significant signs of overheating (brownish) of the 
connector for the lamp power. Performed PCA Microcontroller replacement as per [MD] Service 
Manual. All checks and calibrations passed, instrument working per specification.  There was no 
death or injury. 
[1400] 
Electrical/Elec
tronic 
Y - - N [1402] 
Circuit 
Failure 
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xxx -214 [MFR] received a complaint from a customer about a radiation overexposure of a patient. The 
patient received 2,1 Gy during an examination. The customer decided to stop the procedure when 
they noticed the high dose. Until today there was no patient injury noticed by the customer. 
[2900] Use 
Error 
N [2400] 
Output 
issue 
[2905] Use 
of Device 
Issue 
N [2401] 
Energy 
output to 
patient 
tissue 
incorrect 
xxx -294 On 08/29/2015, the reporter contacted [MFR], alleging a POWER (MOISTURE INGRESS) issue. 
Reportedly, the pump had intermittent power issue and moisture/corrosion was evident in the 
battery compartment. No damages to the battery compartment or cap were noted. There was no 
health consequence to the patient associated with the reported incident, and no medical 
treatment or health care provider intervention was required. Therefore, there is no healthcare 
provider information to report. 
[1400] 
Electrical/Elec
tronic 
Y - [1402] 
Circuit 
Failure 
N [1404] 
Power 
Source 
issue 
 
EVALUATION TERMS/ CODES 
Case No Text MFR L1 
Agree? 
(Y/N) 
JRC L1 MFR L2 
Agree? 
(Y/N) 
JRC L2 
xxx -187 The device has been returned and evaluated by Product Analysis on 06/15/2015 with the following 
findings: A review of the last basal delivery was on 04/28/2015 and the last bolus delivery was on 
04/27/2015. A review of the total daily dose history indicated that insulin delivery totals correctly 
reflected programmed values. The returned battery cap and returned cartridge cap were used to 
complete testing. During testing, there were no Errors, Alarms or Warnings that occurred during a 
24 hour duration test. The pump passed the delivery accuracy test and delivered within required 
range and delivered accurately. The reported, “Inaccurate Delivery” complaint was not duplicated 
during investigation. [MFR] has conducted a review of the device history record for this pump and 
confirmed that it was operating within required specifications at the time of release. 
[26800] No 
medical 
device 
problem or 
failure 
detected 
Y - [26801] No 
medical 
device 
problem 
Y - 
xxx -237 [MFR] investigated the reported issue with the table and found that table top had been replaced a 
week earlier.  During that service event a part (tooth rack) had not been fitted to the new table top 
which should have been transferred from original table top before fitting.  The table top fitted with 
all original parts has been reinstalled and tested, the table was working per factory settings and 
tolerances. This is an isolated incident. 
[26000] 
Human 
factors 
Y - [26007] 
Maintenanc
e 
Y - 
xxx -320 The device has been returned and evaluated by Product Analysis on 10/02/2015 with the following 
findings:  Review of the black box data and download history revealed the last basal delivery was 
[26800] No 
medical 
Y - [26802] No 
medical 
N [26801] 
No 
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recorded on 27 August 2015 at 3:02 PM. The total daily dose amounts added up to correctly reflect 
the user’s programed basal rate target. Low battery and replace battery alarms were present in the 
alarm records.  Several replace battery warnings appeared due to discharged batteries being placed 
in the pump.  On investigation, Ez-Prime steps were successfully performed.  There was no 
overheating, errors, alarms or warnings during the investigation.  The delivery accuracy was found 
to within the required specifications and delivering within range.  All electrical current draws were 
found to be within the required specifications and the pump performed as intended without 
malfunction. The pump was opened for investigation and did not reveal any evidence of damage, 
defect or contamination of the pump’s interior components. Investigation did not duplicate the 
alleged temperature issue. 
device 
problem or 
failure 
detected 
device 
failure 
detected 
medical 
device 
problem 
xxx -310 The device has been returned and evaluated by Product Analysis on 10/09/2015 with the following 
findings: A review of the black box indicated that last basal delivery occurred on 09/15/2015 and 
the last bolus delivery occurred on 09/14/2015. The black box indicated that insulin delivery was 
interrupted on 09/14/2015 from 14:07 to 14:40 due to a cartridge change. The black box also 
indicated that on 09/12/2015 at 19:07 the pump emitted an “Exceeds Max 2 hour limit” warning 
and deliveries resumed at 19:40. A review of the total daily dose history indicated that insulin 
delivery totals correctly reflected programmed values. The pump powered on normally and 
successfully completed a rewind, load, and prime sequence. The pump was exercised for 24 hours 
on a 2unit per hour basal rate and at the end of testing, the basal history correctly showed 2units 
per hour and the total daily dose correctly showed 48units. The pump passed delivery accuracy 
testing and was found to be delivering within required specifications. No defects were found on 
investigation. 
[26800] No 
medical 
device 
problem or 
failure 
detected 
Y - [26802] No 
medical 
device 
failure 
detected 
N [26801] 
No 
medical 
device 
problem. 
xxx -344 The device has been returned and evaluated by Product Analysis on 09/18/2015 with the following 
findings: Multiple call service 052 and 087 alarms were observed in the pump history. The returned 
battery cap was used for investigation. The pump was powered on with the display remaining 
blank.  After approximately 15 minutes, the pump displayed a “Sleep Error” and the remaining 
steps were unable to be completed. The pump was opened and moisture damage was found on 
PCB. Moisture in the pump can be caused by cracks or damage to the pump casing, battery cap, 
display lens or keypad. In the absence of visible damage that would affect the moisture-proof 
features of the pump, a damaged dual vent could allow moisture ingress, and damage to internal 
components or pump structure may allow moisture to migrate between pump compartments. 
There are also user related factors such as the battery cap or cartridge cap not being secured to the 
pump properly which may lead to moisture ingress.  This complaint does not constitute a new 
failure mode; similar confirmed complaints are evaluated via trend and control charting for 
escalation including CAPA. [MFR] has conducted a review of the device history record for this pump 
and confirmed that it was operating within required specifications at the time of release.  
[27300] Other N [25500 
Electrical] 
[27301] 
Other 
N [25502] 
Electrical 
circuitry 
xxx -394 The device has been returned and evaluated by Product Analysis on 08/21/2015 with the following [27300] Other N [26700] [27301] N [26703] 
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findings: A review of the black box indicated no reboots had occurred. The battery cap was not 
returned with the pump for investigation; a test battery cap was used to complete testing. The 
battery compartment was found to be cracked in two places, and there was moisture/corrosion 
found in the battery compartment. Pumps are currently manufactured according to design and 
manufacturing specifications. However some technical modifications/improvements are under 
evaluation to reduce the probability of occurrence of this issue in the near future. One contributor 
appears to be the material of the battery cap O-ring in terms of dimension and hardness.  Another 
potential secondary contributor is the battery spring force.  The cracked battery compartment is 
due to environmental stress cracking of the polymer alloy housing caused by the cumulative effects 
of the inherent design (O-ring dimension and hardness) along with environmental factors 
(temperature, moisture, and contaminants).  The failure modes can be reduced and/or eliminated 
by using an improved battery cap assembly, which reduces the design stress on the housing. [MFR]: 
This is a very complicated issue that requires extensive evaluation, fabrication and then verification. 
There is presently an effort to lower the durometer (hardness) of the battery cap O-ring, which will 
reduce hoop stress on the pump housing. This is strictly a change to the battery cap assembly and is 
neither a material or dimensional change. This potential change can reduce or eliminate the failure 
modes of the housing. This evaluation is ongoing and does not have a completion date identified at 
this time. Moisture was found as part of the investigation. Moisture in the pump from the pump 
casing being damaged/cracked may affect the internal electronics and may cause power problems. 
Moisture ingress does not constitute a new failure mode; similar confirmed complaints are 
evaluated via trend and control charting for escalation including CAPA. Leak testing revealed a leak 
at the battery compartment cracks. The pump powered on but would not hold prime. Additional 
testing for the alleged power issue could not be completed due to inability of the pump to hold 
prime. The pump casing was removed and there was evidence of moisture corrosion found 
throughout the pump.  
Mechanic
al 
Other Fracture 
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4.4 Level 1, 2 & 3 terms: number submitted 
 
Table 5 summarises the number of MIR pilot forms with proposals for new terms at all 
levels, i.e. existing levels one and two of ISO/TS 19218, as well as additional level 3 
proposals. Briefly, of the 741 eligible submissions that contained proposals for new 
'event-type' terms or used one of EDMA's newly introduced 'event-type' terms, 76.2% 
contained proposals for level 3 terms, 11.7% contained proposals for level 1 terms 
(based on using the term 'Other' at level 1 and 2, while proposing a new term), and 
there were 8.9% (66) proposals for level 2 terms (64 based on choosing EDMA's level 2 
terms; 2 based on choosing the term 'Unselect' at level 2 and proposing a new term) 
(Table 5; Fig. 5). 
 
For evaluation terms, 70.9% of submissions contained proposals for new level 3 terms, 
none for level 2 terms and 3.1% with proposals for level 1 terms (Table 5; Fig. 6). There 
were many more submissions for evaluation terms with no new proposals (26%) 
compared to those with event-type terms (3.1%) (Table 5; Figures 5, 6).   
 
 
Table 5. Number and percentage of submitted MIR pilot forms with/without new 'event-type' and 'evaluation' 
terms. n/a: not applicable; total number of eligible forms= 741; indicated percentages reflect only eligible 
forms and values are based on the first entry of terms which were the predominantly chosen ones (see Table 
6; Fig. 7, 8). 
 
 Event-type terms 
Evaluation terms 
 
With 
proposals  
for new 
terms 
With 
EDMA's 
new terms 
Without 
proposals for 
new terms 
With 
proposals for 
new terms 
With 
EDMA's 
new 
terms 
Without 
proposals for 
new terms 
Level 1 87 (11.7%) 0 2 (0.3%) 23 (3.1%) 0 2 (0.3%) 
 
Level 2 
 
2 (0.3%) 64 (8.6%) 0 0 0 2 (0.3%) 
Level 3 565 (76.2%) n/a 21 (2.8%) 526 (70.9%) n/a 188 (25.4%) 
 
 
Figure 5. Percentage of submitted MIR pilot forms with proposals for new level 1, 2 or 3 'event-type' terms. 
Values include EDMA's newly proposed terms and are based on Table 5. 
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Figure 6. Percentage of submitted MIR pilot forms with proposals for new level 1, 2 or 3 'evaluation' terms. 
Values include EDMA's newly proposed terms and are based on Table 5. 
 
For each incident, manufacturers can propose up to three terms in the MIR pilot form to 
describe the incident (event-type terms) or the manufacturer's final investigation 
(evaluation terms). The 1st choice should reflect the primary term, the 2nd choice the 
secondary term, and the 3rd choice the tertiary term. An analysis of the frequency of 
use of these choices gives an indication on how many are sufficient and will be essential 
for future designs of the MIR form. For the analysis of both event-type and evaluation 
terms it is clear that the first choice is predominantly used (Table 6; Figures 7, 8). 
 
Table 6. Number and percentage of submitted MIR pilot forms with entries ('event-type' and 'evaluation' 
terms) at 1st, 2nd or 3rd choice. Total number of eligible forms = 741; indicated percentages reflect number of 
terms relative to the total number of possible terms within the choice level (= 741, number of eligible forms). 
 
 Event-type terms Evaluation terms 
 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 
Choice 1 741 (100%) 737 (99%) 675 (91%) 741 (100%) 738 (99%) 550 (74%) 
Choice 2 36 (4.8%) 36 (4.8%) 18 (2.4%) 69 (9.3%) 69 (9.3%) 48 (6.5%) 
Choice 3 4 (0.5%) 4 (0.5%) 4 (0.5%) 21 (2.8%) 21 (2.8%) 18 (2.4%) 
 
 
Figure 7. Percentage of submitted MIR pilot forms with entries of 'event-type' terms for  
1st, 2nd or 3rd choices. Values are based on Table 6. 
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Figure 8. Percentage of submitted MIR pilot forms with entries of 'evaluation' terms for  
1st, 2nd or 3rd choices. Values are based on Table 6. 
 
 
 
4.5 Submissions by manufacturer and country of incident 
 
The 741 eligible submissions were submitted by 13 manufacturers, five of which have 
the same parent company (Table 7; Fig. 9). One manufacturer submitted significantly 
more MIR pilot forms when compared to others.  
 
Table 7. Number and percentage of submitted MIR pilot forms by the different manufacturers.  
* indicates same parent company 
 
Manufacturer No. submitted Percentage 
Manufacturer 1 * 493 66.5 
Manufacturer 2 * 42 5.7 
Manufacturer 3 * 40 5.4 
Manufacturer 4 * 23 3.1 
Manufacturer 5 * 2 0.3 
Manufacturer 6 32 4.3 
Manufacturer 7 36 4.9 
Manufacturer 8 22 3.0 
Manufacturer 9 5 0.7 
Manufacturer 10 3 0.4 
Manufacturer 11 3 0.4 
Manufacturer 12 39 5.3 
Manufacturer 13 1 0.1 
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Figure 9. Percentage of submitted MIR pilot forms by manufacturer. Values are based on Table 7.  
* indicates same parent company 
 
The 741 eligible submissions originated from 15 countries (Table 8; Figure 10). 
Noteworthy is the heterogeneity in number of files being sent from the various countries 
and the disproportionality between the number sent and the medical technology sales in 
the respective countries (Table 8).  
 
Table 8. Number and percentage of submitted MIR pilot forms by country of incident 
 
Country of incident No. submitted Percentage 
United Kingdom 334 45.1 
Czech Republic 70 9.4 
Italy 42 5.7 
Switzerland 33 4.5 
Ireland 36 4.9 
Sweden 59 8.0 
Spain 49 6.6 
France 57 7.7 
Belgium 14 1.9 
Portugal 7 0.9 
Austria 11 1.5 
Croatia 7 0.9 
Denmark 12 1.6 
Cyprus 2 0.3 
Norway 1 0.1 
not mentioned 7 0.9 
 
  
66.5% 
5.7% 
5.4% 
3.1% 
0.3% 4.3% 
4.9% 
3.0% 
0.7% 
0.4% 0.4% 
5.3% 
0.1% Manufacturer 1*
Manufacturer 2*
Manufacturer 3*
Manufacturer 4*
Manufacturer 5*
Manufacturer 6
Manufacturer 7
Manufacturer 8
Manufacturer 9
Manufacturer 10
Manufacturer 11
Manufacturer 12
Manufacturer 13
 20 
 
 
Figure 10. Percentage of submitted MIR pilot forms by country of incident. Values are based on Table 8. 
 
 
4.6 Analysis of similar incidents and devices on the market 
 
In contrast to the current MEDDEV MIR form, the MIR pilot form contained a section on 
'Similar incidents and devices on the market'. Information on similar incidents is 
expected to help regulators with regard to signal detection and their risk assessment.  
The section's purpose was to allow assessment of the following questions: (1) is the 
identification of similar incidents, according to similarity criteria provided, feasible? This 
includes provision of the number of devices placed on the market and involved in similar 
incidents (also known as sales or denominator data); (2) are such data helpful for 
signal/ risk detection and analysis and, in particular, for coordinated activities in the 
context of a future European database? 
In the context of the pilot, similar incidents are defined as:  
'Incidents occurring with the same device type / variant of a given manufacturer, and 
(1) having the same root cause and the same event type, if the root cause of the original 
incident is known; or (2) having the same event type if the root cause of the original 
incident is unknown; notwithstanding the outcome for the patient, user or other person'.  
To determine how widespread similar incidents have occurred, manufacturers were 
requested to provide similar incident and sales data: (1) in the country in which the 
event occurred; (2) EEA + candidate countries + CH; and (3) worldwide. Additionally, 
these data were requested at specific time periods, which by default were quarters that 
extended over the last year, thereby allowing for determining device problem rates 
(including failures, meaning complete non-performance). 
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A brief analysis of the section on 'Similar incidents and devices on the market' showed 
the following:  
 
 Provision of data 
32% of submissions (234 of the 741 eligible) provided similar incident and/or 
sales data. 
 
 Completeness of data 
Incomplete time period data 
Of the submissions with data, some did not consistently contain incident or sales 
data for each given time period. 
Incomplete sales data 
Not all geographical sales data was provided. Notably, worldwide data was 
frequently missing.  
 
 Format of data 
Variable data: cumulative vs. period-based 
The number of devices placed on the market was often, but not always, 
cumulative (as requested at the onset of the pilot). 
Variable time periods chosen 
When data was provided, the default quarterly time period was most frequently 
used. With agreement of the Competent Authority this could be changed to other 
time periods, and understandably, yearly time periods were observed for a 
manufacturer of orthopaedic devices. However, two-month time periods were 
also observed for no evident reason. 
 
 Issues with the submitted data 
Unclear basis of similar incident numbers 
1. It is unclear how similar incidents were calculated, especially if more than one 
event-type or evaluation term was entered to describe the adverse event. Are the 
similar incident numbers based on the first entered term or the sum of all 
individual terms? It would be interesting to have numbers relating to each 
entered term. 
2. Additionally, in some entries the similar incident data generated appear (from 
the comments given) to be generated using the evaluation term independent of 
the event-type term, and this does not comply with the definition and the 
requested data. 
3. Manufacturers were given the opportunity to use their in-house terms (defined 
as 3rd level term in the pilot) for determining with more specificity the similar 
incidents. Despite this, and based on comments given in several submissions, 
ISO level 2 codes were still used for the basis of the counts. 
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Geographical data anomalies 
In a fraction of submissions, the entered data (for both similar incidents and sales 
data) did not make sense, for example, where the number for a given period 
from 'World' or 'EEA + candidate countries + CH' was smaller than that 'in the 
country in which the event occurred'.  
 
Sales data peculiarities 
Repetition of identical sales data in different time periods in the same 
submissions appear to indicate weaknesses of reporting as it seems highly 
unlikely that exact same numbers are due to chance. One explanation is that 
reporters simply rounded the sales data and that the numbers hence are 
estimates rather than true 'denominator data'. 
 
4.7 Assessment of new event-type terms proposed by 
manufacturers and EDMA 
 
Because a substantial and in-depth analysis of event-type terms had already been 
carried out in the second interim report (based on 415 forms of which 395 were eligible), 
and since there were no marked differences in the type of incidents being reported in the 
forms that followed, this part of the final report is based to a large degree on the earlier 
analysis. 
 
4.7.1 Event-type level 1 terms proposed by manufacturers and EDMA 
 
As mentioned earlier, manufacturers can propose new level 1 event-type terms by first 
choosing 'Other' (term code: 2300) and then proposing a new term. 
Table 9 summarises the analysis of newly proposed event-type level 1 terms. The 
reporter can enter up to three terms to describe the incident. These are defined as 
choices and the 1st choice is used for the primary description.  
Taking all choices together, the analysis shows that 14% of all eligible entered terms 
were proposals by manufacturers for new event-type level 1 terms. An additional 2% of 
entered terms were level 1 event-type proposals that were based on EDMA's newly 
proposed terms (entries for '3000, Operator issue') (Fig. 11). 
 
Table 9. Number and percentage of submitted MIR pilot forms with new event-type proposals for level 1 
terms. Total number of eligible forms = 395; indicated percentages reflect only eligible forms and are based on 
entry of terms for all choices (1, 2 & 3). 
 
 Event-type terms 
 Total number of 
proposed terms 
in level 1 
No. of newly 
proposed 
level 1 terms 
No. of EDMA's 
newly proposed 
level 1 term 
Choice 1 395 56 0 
Choice 2 30 3 8 
Choice 3 3 1 0 
sum 428 60 (14%) 8 (2%) 
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Figure 11. Percentage of submitted MIR pilot forms with proposals for level 1 event-type terms.  
Values are based on Table 9. 
 
 
An analysis of newly proposed level 1 event-type (Table 10) terms is shown below. 
Besides identifying the need for a more elaborate nomenclature, it also shows that a 
number of terms are in fact redundant or patient outcome terms. This implies that the 
reporter of the incident may not have been aware of already existing terms or may have 
associated the 'event-type' term with the patient instead of the device. 
 
Table 10. 'Event-type' level 1 terms proposed by manufacturers (based on choosing 'Other' at level 1&2). L2: 
level 2; L3: level 3; sum of L1 terms = 54; colour coding: red ≥10 entries (≥18% of L1 terms); orange ≥5 
entries (≥9% of L1 terms); yellow ≥3 entries (≥4% of L1 terms). 
 
Level 1 Level 2 Proposed term No. Existing term(s) Comment 
2300, Other 
2301, Other 
(Implant) loosening 3x 
L2: 1601, Migration of 
device or device 
component 
L2: 1602, Osseo-
disintegration Issue 
Possibly valid as 
level 3 term under 
1601:  
'Loosening of 
implant'  
 
 Component 
loosen/broken 
1x L2: 1601, Migration of 
device or device 
component 
L2: 1602, Osseo-
disintegration Issue 
  
 
 
(Implant) breakage 7x 
L1: 2000, Material 
  
Possibly valid as 
level 2 term under 
2000: 'Break' 
 
 
Disassociate/Dislocation 2x 
L2: 1601, Migration of 
device or device 
component 
Likely redundant to 
'loosening of 
implant' 
 
 
Osteolysis 2x 
 Patient outcome 
term 
 
 
ARMD 1x 
 Patient outcome 
term 
 
 
Bone fracture 2x 
 Patient outcome 
term  
 
 
Pain 2x 
 Patient outcome 
term 
 
 
Corneal burn 1x 
 Patient outcome 
term 
 
 
Patient/Surgical 12x 
 Unclear 
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Contamination/ 
Foreign material 
1x 
L2: 2504, Item 
contaminated during 
shipping 
Likely redundant 
 
 
Infection 2x 
L2: 2901, Inadequate or 
inappropriate disinfection 
or sterilization 
Likely redundant 
 
 
Implant noise: 
clicking/squeaking noise 
(while walking/moving 
knee…) 
3x 
L1: 2100, Mechanical Possibly valid as 
level 2 term under 
2100: 
Audible noise 
 
 No product failure 
indicated; Revision  
2x  unclear 
 
 Implant-Implant Fit : 
Cement-implant non-
bonding (no adherence to 
bone after polymerisation 
of cement) 
 L2: 2802, Failure to 
adhere or bond 
Likely redundant; 
2802 to be used 
together with 
components section   
 
 Joint mechanics, poor fit, 
reduced range of 
movement, esp. knee 
extension 
1x L2: 2105, Mechanical Jam Possibly valid as 
level 3 term under 
2105: 
Reduced range of 
movement 
 
 Implant Fit: Mating parts 
don't fit together 
2x L2: 2803, Misassembled Likely redundant 
 
 Left Knee; AE/fixed 
flexion deformity >30 
degrees - to attempt 
MUA 
1x  unclear 
 
 No information provided; 
… insert components 
replaced during surgery 
due to bending upon 
insertion 
1x L2: 2103, Dislodged or 
dislocated 
Likely redundant 
 
 Display: cloudy 1x L2: 2400, Output issue Possibly valid as 
level 3 term under 
2400 and a new 
level 2 term 
'Incorrect display' 
 
 Display: line through 
display 
1x L2: 2400, Output issue  
 
 History/Settings: time/ 
date reset 
1x 
 unclear 
 
 Air bubbles/ leak 1x L2:2104, Leak Possibly valid as 
level 3 term under 
2104: 'Gas leak' 
 
 Aspiration issue 1x L1: 1800, Infusion/Flow Possibly valid as 
level 3 term under 
1800 and a new 
level 2 term 
('Suction Issue')  
 
 Casing condition: 
cracked/ damaged 
1x L2: 2002, Crack Likely redundant; 
2002 to be used 
together with 
components section   
 
 Other, unusual issue 1x  unclear 
 
 Not a device problem 1x  possible 
evaluation term  
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It is interesting to note that new event-type level 1 terms were most frequently 
proposed in the orthopaedic device category (83% of terms in this category). However, 
Table 10 shows that most of the proposed level 1 terms were judged rather to be 
proposals for level 2 or 3 (instead of level 1). Figure 12 provides insight into terms used 
and proposed in this device category.  
 
 
Figure 12. Event-type level 1 terms were predominantly proposed in the orthopaedic device category. This 
was based predominantly on choosing 'other' as level 1 term (83%) and 'other' at level 2. Some level 3 
proposals, however, also branch off existing level 2 terms (e.g. crack, material separation etc.).  
PON: patient outcome nomenclature. 
 
The most frequently used event-type level 1 term proposals relate to (Tables 10 & 11; 
Fig. 13): 
 'breakage'  
 'loosening'  
 'dislocation' 
Variations hereof exist like: 
 'Post-operative/ breakage implant' 
 'Component loosen/broken' 
 'Implant loosening' 
 
In total, 22% of level 1 event-type proposals were for these terms. The term 
'patient/surgical' was the single most frequently proposed term (21%). 16% of proposed 
terms were patient outcome terms (Table 11; Fig. 13). 
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Table 11. Grouping of event-type level 1 term proposals by manufacturers 
Terms No. 
submitted 
Percentage 
patient outcome term instead of event-type term 9 16 
breakage-associated term 7 13 
loosening-associated term 5 9 
infection/contamination- associated term 4 7 
'patient/surgical' term 12 21 
other terms 19 34 
 
 
 
 
Figure 13. Percentage of grouped event-type level 1 term proposals. Values are based on Table 11. 
 
 
4.7.2 Event-type level 2 terms proposed by manufacturers and EDMA 
 
As mentioned earlier, manufacturers could propose new level 2 event-type terms by first 
selecting the appropriate level 1 term, then selecting any available second level term 
(pull-down menu) and after entering a proposal for a new second level term in the free-
text space (space dedicated for level 3 term proposals), the chosen second level term 
had to be changed to 'unselect'. Because this procedure is not particularly user-friendly 
it may explain why few or no proposals were made by manufacturers. 
Table 12 summarises the analysis of newly proposed event-type level 2 terms. Only 1 
event-type level 2 term proposal was made by a manufacturer (Table 13), while 35 
other new level 2 proposals (8%) originated from EDMA newly proposed terms (Tables 
12 & 14). 
  
16% 
13% 
9% 
7% 21% 
34% 
patient outcome term instead
of event-type term
breakage-associated term
loosening-associated term
infection/contamination-
associated term
'patient/surgical' term
other terms
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Table 12. Number and percentage of submitted MIR pilot forms with new event-type proposals for level 2 
terms. Total number of eligible forms = 395; indicated percentages reflect entries from eligible forms and are 
based on entries at all choices (1st, 2nd and 3rd). 
 
 Event-type terms 
 
Total number of 
proposed terms 
in level 2 
With newly 
proposed 
level 2 terms 
With EDMA's 
new level 2 
term 
Choice 1 392 1 25 
Choice 2 29 0  9 
Choice 3 3 0 1 
sum 424 1 (0.2%) 35 (8%) 
 
 
 
Table 13. 'Event-type' level 2 terms proposed by manufacturers (based on choosing 'Unselect' at level 2) 
 
Level 1 Level 2 Proposed terms No. Alternative terms 
Comment 
1400, 
Electrical/Electro
nic 
 Signs of overheating (Issue 
associated with 
overheating of device or 
parts of the device e.g. 
melted, discoloured 
(brownish)) 
1x L1: 2700, Temperature 
L2: 2701, Burned Device 
or Component 
L2: 2705, Overheat of 
Device or Device 
Component 
Redundant to 
2705 
 
 
Of the 12 new 'event-type' terms proposed by EDMA, 5 were used by manufacturers 
(Table 14; Fig. 14).   
 
 
Table 14. EDMA's 'event-type' level 2 terms selected by manufacturers. Sum of all entries = 424 (see Table 
11); indicated percentages reflect entries from eligible forms and are based on entries for all choices (1st, 2nd, 
and 3rd). 
 No. submitted Percentage 
Discrepant negative (2406) 10 2.4 
Discrepant positive (2404) 1 0.2 
Discrepant high (2405) 10 2.4 
Reproducibility issue (2408) 6 1.4 
Splash (3001) 8 1.9 
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Figure 14. Percentage of submitted MIR pilot forms using EDMA's new 'event-type' terms. 
Values are based on Table 13. 
 
A closer look at the terms indicated in Table 14 and Figure 14, as well as their respective 
definitions, clearly shows the need for a revision of the definitions. The terms 'Discrepant 
negative (2406)', 'Discrepant positive (2404)', and 'Discrepant high (2405)' are defined 
identically: 'Issue associated with end results provided by the device'. Additionally, the 
term 'Discrepant low' (2407), which was so far not used in the pilot, has the same 
definition. 
 
4.7.3 Event-type level 3 terms proposed by manufacturers 
 
After choosing appropriate level 1 and 2 terms the manufacturer can propose new event-
type level 3 terms in a dedicated space. 
Some of the level 3 event-type terms proposed (Table 15) appear to be more frequently 
used than others. In some cases, this is related to the high number of MIR pilot forms 
submitted by one single manufacturer and which also concern the same device. 
 
Table 15. 'Event-type' level 3 terms proposed by manufacturers. L2: level 2; L3: level 3; sum of L3 terms = 
295; colour coding: red ≥15 entries (≥5% of L3 terms); orange ≥7 entries (≥2.4% of L3 terms); yellow ≥3 
entries (≥1% of L3 terms). 
 
Level 1 Level 2 Proposed terms No. Alternative 
terms 
Comment 
1000, 
Activation or 
Positioning or 
Separation 
1002, Failure to 
Activate 
Button/keypad: tactile 
changes/ unresponsive 
45x  Possibly valid: 
'Failure to touch 
activate button/ key' 
under 1002 
 
 Button over responsive 1x  Possibly valid: 
In combination with a 
new L2 ('Over-
activation') under 1000 
0
0.5
1
1.5
2
2.5
3
Discrepant neg.
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 Button/keypad: tactile 
changes with moisture 
3x 1500, External 
conditions 
Moisture issue could 
be entered separately 
as new L3 ('moisture 
damage') under a new 
L2 ('moisture or 
humidity problem') 
under 1500. 
 
 Button damage prior to 
tactile change 
2x  Appears as an 
evaluation term 
 
 Blank display screen 5x 2403, No Device 
Output 
Possibly valid as 'no 
display' but only as L3 
under 2403 
 
 Failure To Shock Or 
Properly Shock  
1x 1404, Power 
source issue 
 
Possibly valid as L3 
('Failure to properly 
shock') under 1404 
 
 Failure to power up  1x 
 
1404, Power 
source issue 
 
Possibly valid as 
'Failure to power-up' 
under 1404 
 
1003, Failure to 
Separate 
Unfolding issue 
 
3x  Possibly valid: 
'Failure to unfold' 
under 1003  
 
1005, Delayed 
Activation 
Button/keypad- tactile 
changes/ unresponsive 
12x 
 
 Unclear if proposed 
term relates to a 
delayed activation (see 
1005) or failure to 
activate (unresponsive) 
1300, 
Connection 
or Fitting 
1301, 
Connection 
issue 
Power- damage 1x 1404, Power 
source issue 
 
Unclear 
 
 SITE/SET/CART: O-ring 
leak 
1x  Possibly an evaluation 
term 
 
1305, Loose or 
intermittent 
connection 
Intermittent power 1x  Possibly valid: 
'intermittent power' 
under 1305 
1400, 
Electrical/ 
Electronic 
1402, Circuit 
Failure 
No power 4x 1404, Power 
source issue 
 
Possibly valid as 
'Failure to power-up' 
under 1404 
 
 Intermittent power 4x  1404, Power 
source issue 
 
Possibly valid: 
'intermittent power' 
under 1402 
  
 Intermittent power with 
moisture 
ingress/intrusion 
3x 1500, External 
conditions 
Moisture issue could 
be entered separately 
as new L3 ('moisture 
damage') under a new 
L2 ('moisture or 
humidity problem') 
under 1500. 
 
 No power – damage with 
moisture ingress 
1x   
 
 Power – damaged with 
moisture ingress 
2x   
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 Power – moisture ingress 1x   
 
 Power – damage 1x  Unclear 
 
 Circuit Failure 1x  Likely redundant 
 
1403, Device 
Sensing Issue 
Failed to alarm occlusion 1x 2601, Device 
alarm system 
issue 
1802, Improper 
flow or infusion 
Possibly valid but to be 
entered separately: L3 
under 2601: 
'Defective alarm' and 
L3 under 1802: 
'Obstruction within 
device' 
 
 Loss of signal 1x  Possibly valid: 
'Failure to detect 
signal' 
 
1404, Power 
Source Issue 
Power issue 1x 
  
 Likely redundant 
 
 No power 7x  Possibly valid as 
'Failure to power-up' 
 
 Intermittent power 8x   Possibly valid as 
'Intermittent power'  
 
 Power-(damage with) 
moisture ingress 
11x 1500, External 
conditions 
Moisture issue could 
be entered separately 
as new L3 ('moisture 
damage') under a new 
L2 ('moisture or 
humidity problem') 
under 1500. 
 
 Power - damage 5x  Unclear 
 
 Premature battery 
depletion/ longevity 
1x   Possibly valid as 
'Internal battery of 
device prematurely 
depleted' 
1600, 
Implantable 
Device 
Failure 
1601, Migration 
of Device or 
Device 
Component 
implant: tilted 
(migration/tilting of cup) 
1x  Possibly valid as 
'Unintended tilting of 
implant cup' 
 
 Implant tilted 1x   
 
 Break 1x  unclear 
 
1602, Osseo-
disintegration 
Issue 
Loosening of implant 1x 1601, Migration 
of Device or 
Device 
Component 
Possibly valid as 
'loosening of implant' 
under 1601  
1700, 
Incompatibilit
y 
1703, Patient-
Device 
Incompatibility 
Visual Disturbance: 
anomalies as experienced 
by patient in their field of 
vision 
1x 
 
 Patient outcome term 
 
 Loss of capture 1x 1400, Electrical/ 
electronic 
Possibly valid as new 
Level 2: 'Failure to 
capture' under 1703 
 
 Pacing threshold pro 1x  unclear 
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1800, 
Infusion/Flow 
1802, Improper 
Flow or Infusion 
History/Settings issue-
Inaccurate delivery 
13x 1202, 
Programming 
issue 
Possibly valid but 
should be entered 
separately as (1)  L3 
('Inaccurate delivery' 
under 1802) and (2) L2 
(1202, 'Programming 
issue')  
 
 Catheter shaft, restricted 
flow 
1x  Possibly valid as L3: 
'Restricted flow rate' 
under 1802 
 
1805, Excessive 
Flow or 
Overinfusion 
Overdelivery 1x  Likely redundant 
 
 Overinfusion 
(> 30% above expected 
rate) 
1x   
 
1806, 
Insufficient 
Flow or Under-
infusion 
Underdelivery 
 
1x  Likely redundant 
2000, 
Material 
2001, Burst Balloon, rupture 2x  Burst is defined as 
rupture 
 
 Rupture 1x   
 
2002, Crack Catheter shaft, crack 1x  Likely redundant 
 
 Display damaged 6x  Likely redundant: 
component codes to 
be used together with 
2002 
 
 Display: damage with 
moisture ingress 
1x 1500, External 
conditions 
Moisture issue could 
be entered separately 
as new L3 ('moisture 
damage') under a new 
L2 ('moisture or 
humidity problem') 
under 1500. 
 
 Power: damage with 
moisture ingress 
1x  Unclear: power source 
cracked with moisture 
ingress? 
 
 Break 3x  Possibly valid as level 2 
term under 2000: 
'Break' 
 
2003, Degrade Line through display 8x 2400, Output 
issue 
Possibly valid as L3 
under L1 2400, and 
new L2: 'Incorrect 
display'  
 
 Display: segments missing 8x   
 
 Display: damage 2x  Needs to be further 
specified 
 
 Display: dim/ fading/ 
colour spectrum 
2x 2400, Output 
issue 
Possibly valid as L3 
under L1 2400, and 
new L2: 'Incorrect 
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display'  
 
 Display: blank screen 2x 2403, No Device 
Output 
Possibly valid as 'no 
display' but only as L3 
under 2403 
 
 Display: cloudy 1x 2400, Output 
issue 
Possibly valid as L3 
under L1 2400, and 
new L2: 'Incorrect 
display' 
 
 Display: cloudy with 
moisture 
1x 1500, External 
conditions 
Moisture issue could 
be entered separately 
as new L3 ('moisture 
damage') under a new 
L2 ('moisture or 
humidity problem') 
under 1500. 
 
 Display: scratched 1x  Possibly valid L3 as 
'Scratched material' 
under a new L2: 
'material deformation'; 
Components code 
should define affected 
component  
  
2004, Material 
discoloured 
Display: dim/ fading/ 
colour spectrum 
48x 2400, Output 
issue 
Possibly valid as L3 
under L1 2400, and 
new L2: 'Incorrect 
display' 
 
 Display: fading/ colour 
spectrum 
2x   
 
 Display: dim/ fading/ 
colour spectrum with 
moisture 
4x 1500, External 
conditions  
Moisture issue could 
be entered separately 
as new L3 ('moisture 
damage') under a new 
L2 ('moisture or 
humidity problem') 
under 1500. 
 
 Cloudy with moisture 1x  Needs to be further 
specified 
 
 Cloudy 1x  Needs to be further 
specified 
 
 Display: inkspot 1x 2400, Output 
issue 
Possibly valid as L3 
under L1 2400, and 
new L2: 'Incorrect 
display' 
 
 Display: cloudy 1x 2400, Output 
issue 
Possibly valid as L3 
under L1 2400, and 
new L2: 'Incorrect 
display' 
 
2005, Material 
Fragmentation 
Display: segments missing 2x 2400, Output 
issue 
Possibly valid as L3 
under L1 2400, and 
new L2: 'Incorrect 
display' 
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 Brea 1x  Possibly valid as level 2 
term under 2000: 
'Break' 
 
2007, Material 
separation 
Instrument breakage 1x   
  
 Detachment of device 
component 
4x L1: 2100, 
Mechanical 
L2: 2102, 
Detachment of 
device or device 
component 
Likely redundant to L2: 
2102 
 
 
 Display: damage 1x  Needs to be further 
specified: break? 
 
 Core separation 1x  Unclear 
2100, 
Mechanical 
2102, 
Detachment of 
Device or 
Device 
Component 
Disconnection of the 
Implant 
1x 1602, Osseo-
disintegration 
Issue 
See above: 'Loosening 
of implant' under 
1602, Osseo-
disintegration Issue 
 
2104, Leak Catheter shaft, 
Leakage blood 
1x  'blood leakage' needs 
to be further explored 
 
 Leak 8x  Likely redundant 
 
2105, 
Mechanical Jam 
Mechanical jam 1x  Likely redundant 
2400, Output 
Issue 
2402, Incorrect 
or Inadequate 
Result 
History settings issue 2x 1202, 
Programming 
issue 
To be entered 
separately: 1) 2402, 
incorrect result; 2) 
1202, programming 
issue  
 
 time and date issue 1x 1200, 
Computer 
software 
Possibly valid under L1: 
1200 
 
 Call service alarm issue 5x 
2601, Device 
Alarm 
System Issue 
Possibly valid under 
2601 
 
 Audio tone/ Vibration 
issue  
4x 2100, Mechanical 
2107, Unintended 
movement 
Possibly valid under 
2100: noise;  
and under 2107: 
vibration 
 
2406, 
Discrepant 
negative 
Cross-match 8x  L2:2406  EDMA's IVD-
related term. 
Possibly valid L3.  
2600, 
Protective 
2601, Device 
Alarm System 
Issue 
Audio tone/ Vibration 
issue 
(no sound; weak or 
intermittent vibration) 
4x 
 Possibly valid:  
'Not audible alarm' 
'Weak alarm vibration' 
under 2601 
 
 Frequent/ persistent 
occlusion 
1x 1802, Improper 
Flow or Infusion 
To be filled in 
separately: 2601 & 
1802 
2700, 
Temperature 
2705, Overheat 
of Device or 
Device 
Temperature – Moisture 
ingress 
1x 1500, External 
conditions  
Moisture issue could 
be entered separately 
as new L3 ('moisture 
 34 
 
Component damage') under a new 
L2 ('moisture or 
humidity problem') 
under 1500. 
 
 Temperature – physical 
damage 
1x  Possibly valid: 
Overheating with 
physical damage 
 
 Temperature – no 
physical damage 
1x 2704, Insufficient 
cooling 
Possibly valid: 
Overheating with no 
physical damage 
2800, 
Unintended 
Function 
2802, Failure to 
adhere or bond 
Implant-Implant Fit : 
Cement-implant non 
bonding 
 
 
1x  Likely redundant; 2802 
to be used together 
with components 
section   
2900, Use 
Error 
2906, Device 
inoperable 
Device displays error 
message 
7x 2801, Device 
displays incorrect 
message 
Possibly valid: 
Device displays error 
message 
 
2905, Use of 
Device Issue 
SITE/SET/CART: air 
bubbles filling 
1x  unclear 
 
 
 
4.7.4 The need for a modular approach regarding hierarchical structure 
of nomenclatures 
 
The analysis of newly proposed terms prompted us to reflect on a key issue regarding 
the structure of nomenclatures. It is important to pursue a 'modular approach' when 
proposing new terms and when maintaining nomenclatures, otherwise one risks to 
develop an overly detailed set of terms for describing incidents.  
 
A good example relates to terms concerning power (Table 15). The power-related level 3 
event-type proposals are shown in Figure 15. Often proposals consist of combinations of 
single terms. For example, both 'no power' and 'no power with moisture ingress' can be 
found within the proposals. The same applies for the case of 'intermittent power'. As 
there is the possibility to enter up to three terms to describe the event (choices 1-3), the 
modular approach implies to separate the described event into separate modules (or 
choices) (Figure 16). 
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Figure 15. Event-type level 3 term proposals related to power. 
 
 
 
 
 
 
Figure 16. The modular approach explained using a proposed level 3 event-type term relating to an electrical 
power issue (no power- damage with moisture ingress). For the sake of not creating an overly detailed set of 
terms, a guiding principle for nomenclature development/maintenance would be to aim for a modular 
architecture of the terminology, i.e. splitting the described issues into separate modules: 'failure to power-
up' AND 'moisture damage'. 
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4.8 Assessment of new evaluation terms proposed by 
manufacturers and EDMA 
 
Because a substantial and in-depth analysis of evaluation terms had already been 
carried out in the second interim report (based on 415 forms, of which 395 are eligible), 
and since there were no marked differences in the type of incidents being reported in the 
forms that followed, this part of the final report is largely based on the earlier analysis. 
 
4.8.1 Evaluation level 1 terms proposed by manufacturers and EDMA 
 
Manufacturers can propose new level 1 evaluation terms by first choosing 'Other' (term 
code: 27300) and then proposing a new term.  
Table 16 summarises the analysis of newly proposed evaluation level 1 terms. The 
reporter can enter up to three terms to describe the results of the manufacturer's 
investigation. These are defined as choices and the 1st choice is used for the primary 
description. Taking all choices together, the analysis shows that 3% of all eligible 
entered terms were proposals by manufacturers for new evaluation level 1 terms. This is 
much less when compared to event-type terms (14%; Table 9, Figure 17) 
 
Table 16. Number and percentage of submitted MIR pilot forms with new proposals for level 1 terms. n/a: not 
applicable; total number of eligible forms = 395; indicated percentages reflect only eligible forms and are 
based on entry of terms for all choices (1, 2 & 3). 
 
 
Evaluation terms 
 
Total number 
of proposed 
terms in level 1 
No. of newly 
proposed 
level 1 terms 
No. of EDMA's 
newly proposed 
level 1 term 
Choice 1 395 12 n/a 
Choice 2 35 1 n/a 
Choice 3 9 0 n/a 
sum 439 13 (3%)  
 
 
 
Figure 17. Percentage of submitted MIR pilot forms with proposals for level 1 evaluation terms. For 
comparison, event-type terms were included. Values are based on Table 9 and 16. 
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An analysis of newly proposed level 1 evaluation terms is shown below (Table 17). There 
were 12 new proposals, however, they often appeared redundant or to be event-type 
terms. The most frequently proposed level 1 evaluation term was 'Moisture in pump'. It 
may be better to redefine it as 'moisture issue' and to categorise it as a level 3 term 
under 26704, 'Leakage/seal'. Alternatively, it could be rephrased to 'Improper humidity' 
and placed under a new L1: 'Environment problem'. 
 
Table 17. 'Evaluation' level 1 terms proposed by manufacturers (based on choosing 'Other' at level 1 & 2). L2: 
level 2; L3: level 3; Sum of L1 terms = 12; colour coding: red ≥3 entries (≥25% of L1 terms); orange ≥2 
entries (≥16% of L1 terms). 
 
Level 1 Level 2 Proposed term No. Alternative terms Comment 
27300, Other 
27301, Other  Other - packaging 2x L2: 26506, Packaging 
problem 
L2: 25303, Packaging 
Likely 
redundant 
 
 Loosening 2x  Event-type term 
 
 Component loosen/ 
broken 
1x  Event-type term 
 
 Inaccuracy confirmed 1x  Needs to be 
further 
specified 
 
 Moisture in pump 5x L2: 26704, Leakage/ 
Seal 
Possibly valid as 
level 3 term 
under 26704; 
Component 
codes to be 
used to identify 
pump 
 
 Lines in Display 1x  Event-type term 
 
 
4.8.2 Evaluation level 2 terms proposed by manufacturers and EDMA 
 
No 'evaluation' level 2 terms were proposed by manufacturers. As for event-type terms 
(Table 11), the relative lack of proposals is likely a result of the cumbersome procedure 
to introduce new level 2 term proposals, which proved to be not very user-friendly. 
Additionally, no forms were submitted with EDMA's new evaluation terms (Table 18). 
 
 
Table 18. Number and percentage of submitted MIR pilot forms with new proposals for level 2 terms. total 
number of eligible forms = 395; indicated percentages reflect entries from eligible forms and are based on 
entries for all choices (1st, 2nd and 3rd). 
 
 Evaluation terms 
 Total number of 
proposed terms in 
level 2 
With newly 
proposed level 2 
terms 
With EDMA's new 
level 2 term 
Choice 1 395 0 0 
Choice 2 35 0 0 
Choice 3 9 0 0 
sum 439 0 (0%) 0 (0%) 
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4.8.3 Evaluation level 3 terms proposed by manufacturers 
 
Some of the level 3 evaluation terms proposed by manufacturers appear to be more 
frequently used than others. For example, the term 'device not returned to 
manufacturer' and variations thereof ('device not returned for investigation' or 'product 
not returned') were used in a significant number of the submissions (Table 19).  
Table 19. 'Evaluation' level 3 terms proposed by manufacturers. L2: level 2; L3: level 3; Sum of L3 terms = 
265; colour coding: red ≥15 entries (≥5.6% of L3 terms); orange ≥7 entries (≥2.6% of L3 terms); yellow ≥3 
entries (≥1.1% of L3 terms). 
Level 1 Level 2 Proposed terms No. Alternative 
terms 
Comment 
25500, 
Electrical 
25501, Electrical 
component 
Defective capacitor 
1x  Likely redundant to 
25501; capacitor to be 
defined in component 
codes  
 
25502, Electrical 
circuitry 
Moisture in pump 
1x L2: 26704, 
Leakage/seal 
Better placed under 
26704 
 
25503, Electrical 
contact 
Damaged battery cap 
1x L2: 26601, 
Degradation 
problem 
L2: 26703, 
Fracture 
Likely redundant; 
battery and cap to be 
defined in component 
codes and damage 
needs to be further 
specified (if worn out 
then 26601,…) 
 
25507, Power 
source — loss of 
power 
Power Source Problem 
1x  Likely redundant 
26000, Human 
factors 
26001, Abnormal 
use 
Abnormal use 
1x  Likely redundant 
 
26006,Installation 
problem 
User error 
1x L2: 26014, Use 
error 
Likely redundant to 
26006; 26014 could be 
entered separately 
 
26009, Patient 
anatomy/ 
physiology 
User error: orientation of 
implant; Orientation of 
implant not optimal 
1x  Possibly valid L3 under 
26009:  
Non-optimal 
orientation of implant 
 
26014, Use error Orientation/ alignment of 
implant 
1x   
26600, 
Materials, 
chemistry 
26601, 
Degradation 
problem 
Dim/discoloured display 
19x  Event-type term 
 
 Unidentified Display 
Failure 
4x L2: 29001, 
Unidentified 
Likely redundant: 29001 
could be entered 
separately 
 
 Unidentified display 
failure (Faded Colour/Dim 
Display) 
3x   
 
 Moisture in pump 
2x L2: 26704, 
Leakage/seal 
Better placed under 
26704  
 
 Peeling display lens cover 
1x  Event-type term 
 
 Display damaged 
1x  Event-type term 
 
 Scratched display lens 
(scratches on lens) 
1x  Event-type term 
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 Battery compartment 
crack 
1x L2: 26703, 
Fracture 
Event-type term 
 
26604, Reactivity 
problem 
The most probable root 
cause is sample-related, 
the antibody being weak 
and/or at detection limit 
of the reagents & 
technique used, 
associated with the 
preparation of the cell 
suspension or a 
combination of both. 
2x  Possibly valid as L3 
under 26604: 
Discrepant reaction 
likely due to weak 
antibody and/or sample 
preparation  
 
 
The root-cause of the 
discrepant negative 
reactions in crossmatch 
obtained for plasma from 
patient with donor is 
determined to be a use 
error.  The customer 
manually altered a 
condition code posted by 
the analyser  
1x L2: 26014, Use 
error 
Possibly valid as L3 but 
under 26014: 
Manual alteration of 
device condition codes  
 
 
The root-cause of the 
discrepant negative 
reaction in crossmatch 
obtained for plasma from 
patient with donor could 
not be determined, 
although it could not be 
excluded it is either 
sample-related, the 
antibody being weak 
and/or at the detection 
limit of the reagents and 
technique used or it is 
associated with the 
preparation of the cell 
suspension from the 
donor cells or a 
combination of both. 
2x  Possibly valid as L3 
under 26604: 
Discrepant reaction 
likely due to weak 
antibody and/or sample 
preparation  
  
26700, 
Mechanical 
26701, 
Component 
malfunction 
Vibration motor 
alignment 
1x  Possibly valid as L3 
'vibration problem' 
under new L2 'stress 
problem' under 26700;  
Motor to be defined 
separately in 
component codes 
 
 
Cold/cracked Solder on 
Piezo 
1x  Better placed under 
26702 
 
 
inverted button contact 1x L2: 26501, 
Assembly 
problem 
Possibly valid under 
26501; button to be 
specified under 
component codes 
 
 
Failed Display Connector 1x L2: 26202, 
Disconnection 
Likely redundant to 
26202; Display to be 
specified using 
component codes 
 
 
Damaged Display Screen 1x  Possibly event-type 
terms 
 
 
component failure 1x  Likely redundant to 
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26701 
 
 
bolus button damage 1x  Possibly event-type 
terms 
 
26702, Fatigue 
Material fatigue 1x  Likely redundant to 
26702 
 
 
Cold/cracked Solder on 
Piezo 
1x  Possibly valid as L3 
under 26702 
 
 
Battery compartment 
crack 
2x  Better placed under 
26703, fracture; battery 
to be defined in 
component codes 
 
 
Damaged battery 
compartment 
1x  Possibly an event-type 
term; battery 
compartment to be 
specified using 
component codes 
 
 
Damaged Pump Case 3x  Possibly event-type 
term; Pump case to be 
specified using 
component codes 
 
 
scratched display lens 1x  Possibly event-type 
terms  
 
 
Damaged display screen  2x  Event-type term 
 
26703, Fracture 
battery compartment 
cracked 
7x  Likely redundant to 
26703; Battery 
compartment to be 
specified separately 
using component 
codes; L2: 26703 better 
placed as L3 under new 
L2: 'stress problem' 
 
 
battery compartment 
cracked with moisture 
intrusion 
1x  Moisture issue to be 
entered separately 
possibly under 26704, 
or alternatively it could 
be rephrased to 
'Improper humidity' 
and placed under a new 
L1: 'Environment 
problem' 
 
 
Bolus button cover 
detached/missing 
1x   Possibly valid as  
'missing device 
component' 
 
26704, 
Leakage/seal 
Moisture in pump 5x  Possibly valid as L3 
'Moisture issue' under 
26704. Pump to be 
specified using 
component codes; 
Alternatively 'moisture 
issue' could be 
rephrased to 'Improper 
humidity' and placed 
under a new L1: 
'Environment problem'  
 
 
Display Lens Leak 1x  Likely redundant, 
display and lens to be 
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defined via component 
codes 
 
26705, Wear 
Damaged Battery Cap 1x  Likely redundant, 
battery and cap to be 
specified in component 
codes 
 
 
Button Contact Defect 1x  Likely redundant, 
button to be defined in 
component codes 
26800, No 
medical device 
problem or 
failure detected 
26801, no 
medical device 
problem 
- No defect found 
- No defect found on 
testing 
- No device problem 
determined 
- Undetermined: no 
product problem 
identified 
-complaint not duplicated 
-not able to reproduce 
issue 
55x  Possibly valid, 
L1 and L2 terms needs 
to be redefined to 
account for device 
having been tested/ 
investigated with no 
evidence of failure  
 
 
Actual Device Not 
Evaluated 
1x  Possibly valid, 
Term needs to be 
redefined to account 
for device not having 
been returned for 
investigation  
 
 
Battery compartment 
cracked 
1x  Better placed under 
26703 
 
26802, no 
medical device 
failure detected 
- Device not returned  
- Device not returned for 
investigation 
- No device returned for 
investigation 
- Product not returned 
- No Results Available 
Since No Evaluation 
Performed 
40x - Possibly valid, 
terms need to be 
redefined to account 
for device not having 
been returned for 
investigation  
 
 
No sample 8x  Possibly valid, 
term needs to be 
redefined to account 
for device/sample not 
having been returned 
for investigation  
 
 
- Undetermined: 
insufficient information 
- Unable to investigate 
- Not confirmed 
9x - Possibly valid, 
Appears as a result of 
device not being 
returned for 
investigation. Need for 
redefining terms 
 
 
Retain Product Tested -- 
Missing or inadequate 
information 
1x  unclear 
 
 
-No fault found on testing 
-no defect found 
57x  Possibly valid, 
Terms needs to be 
redefined to account 
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-unable to reproduce 
during investigation 
- Undetermined : No 
Product Problem 
Identified 
- no systematic failure of 
product or analyser to 
perform as intended 
- Undetermined : No 
Product Problem 
Identified 
for device having been 
tested/ investigated 
with no evidence of 
failure 
 
 
Unable to adequately 
investigate due to an 
unrelated failure 
1x  Possibly valid 
 
 
Low voltage in 
replacement battery 
and/or unacknowledged 
Warning/Alarm/Reminde
r observed in black box 
1x 
L2: 27101, 
Alarm 
Possibly better placed 
under 27101 
29000, 
Unidentified 
29001, 
Unidentified 
- Undetermined 
 
 3x 
 Likely redundant  
 
 
- Root cause could not be 
identified 
 
 Likely redundant 
 
 
- Sample not returned 
- Device not returned - no 
evaluation could be 
performed 
3x  Possibly valid, 
Terms need to be 
redefined to account 
for device not having 
been returned for 
investigation 
 
 
-Unable to reproduce 
during Investigation 
-Device is tested for 
functionality and pass. 
-Unable to confirm or 
duplicate the complaint 
during investigation 
6x  Possibly valid, 
Terms needs to be 
redefined to account 
for device having been 
tested with no evidence 
of failure 
 
 
Pump alarmed preventing 
testing; Unable to test 
owing to an unrelated 
fault 
1x  Possibly valid 
 
Table 19 shows that the most frequently proposed level 3 evaluation term relates to the 
term 26800, 'No medical device problem or failure detected'. This seems to indicate 
either a need for higher resolution (granularity) or an inadequacy of these terms and 
their definitions. This prompted us to take a closer look at them. 
 
  
 43 
 
4.9 Resolving the most frequently encountered nomenclature 
issue 
 
Figure 18 shows that the most frequently encountered terms within the MIR pilot form 
relate to the evaluation term 26800, 'No medical device problem or failure detected' 
(65% of terms), and the two terms branching off this level 1 term: 26801 (18% of 
terms) and 26802 (46% of terms). 
 
 
Figure 18. Most frequently encountered terms within the MIR pilot form relate to the  
level 1 evaluation term 26800. 
 
Figures 19 and 20 show the different level 3 evaluation terms proposed by 
manufacturers which relate to the level 1 term 26800, and to its respective level 2 terms 
26801 (Fig. 19), and 26802 (Fig. 20). Their frequency of use is also shown (percentage 
of MIR pilot forms with the proposed term). The terms have also been rearranged in 
Figure 21 as an effort for a better fit for similarity.  
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Figure 19. Proposed level 3 evaluation terms related to the level 2 term 26801. Boxed are terms that are 
distinctly different from the others and possibly imply that no investigation took place. 
 
 
 
 
 
Figure 20. Proposed level 3 evaluation terms related to the level 2 term 26802. Boxed are terms that are 
distinctly different from the others and possibly imply that no investigation took place. 
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Figure 21. Rearrangement of level 3 terms into two distinct categories, defining  
whether or not an investigation took place. 
 
A closer look at the relevant evaluation terms (26800, 26801, & 26802) and their 
definitions shows that there is room for improvement in their naming and definition. A 
strategy, which lies at the basis of new terminology proposed by JRC to resolve this 
issue is shown in Figure 22. This strategy would be in line with the philosophy embodied 
in the current FDA's evaluation terms and it remains unclear why ISO decided, when 
using the FDA evaluation terms as a basis for their technical specifications, to abolish 
terms that, unambiguously, allow to report whether or not an investigation of the device 
or the batch has taken place. 
 
 
Figure 22. Strategy used for JRC's new terminology proposal (modifications to 26800, 26801 & 26802). 
 
Figure 23 shows the proposed new terminology by JRC for level 1, 2 and 3 evaluation 
terms and their definitions, which could provide more clarity for manufacturers when 
reporting incidents using the level 1 term 26800, and its respective level 2 terms 26801 
& 26802.  
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At a first level, there should be a clear distinction made between a device that functioned 
as intended and a device that did not function as intended. At the second level, there 
should be a clear distinction made on whether an investigation for gathering evidence of 
a failure took place or not. At the third level, a new evaluation term could be introduced 
to provide an added level of detail describing that no investigation took place because 
the device was not returned to the manufacturer.  
 
 
Figure 23. JRC proposal for modifications and additions to the level 1 term 26800 and its  
respective level 2 terms 26801 & 26802. 
 
These new terms and their definition should resolve some of the issues faced by 
manufacturers, and should remove redundancies as shown in the following figure (Figure 
24). 
 
 
Figure 24. Regrouping of terms proposed by manufacturers using new terms/ definitions  
proposed by JRC and the removal of redundancy. 
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4.10 Terms to be considered for incorporation in the future global 
nomenclature for describing incidents with devices (IMDRF 
initiative) 
 
As part of ongoing efforts to develop a globally used nomenclature (International Medical 
Device Regulators Forum [IMDRF] nomenclature) for describing incidents with devices, 
the proposed terms of the pilot that have been deemed valid when compared to ISO/TS 
19218 have subsequently also been compared to FDA terms to identify possibly 
missing/better terms (Figure 25). 
The event-type terms were compared to FDA's device problem terms (Table 20), while 
the evaluation terms were compared with FDA's evaluation result and conclusion terms 
(Table 21). FDA's terms were last accessed on 31 March 2016 at: 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/Repo
rtingAdverseEvents/EventProblemCodes/ucm134751.htm 
Additionally, EDMA's event-type and evaluation terms were compared with FDA's terms 
(Table 22). 
 
 
 
Figure 25. Workflow used to identify terms that could be incorporated into the  
ongoing development of IMDRF's nomenclature. 
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Table 20. Event-type terms proposed by manufacturers and considered to be valid (when compared to ISO/TS 
19218-1), which were subsequently compared to FDA's device issue terms and evaluated for consideration for 
use in a future globally used nomenclature. Cells with identical/ similar terms are shaded. 
 
Pilot Comparison with FDA's terms  
Level 1 Level 2 Proposed 
level 3 
Level 1 Level 2 Level 3 Comment 
Activation or 
Positioning or 
Separation 
(1000) 
Failure to 
activate 
(1002) 
Button/keypa
d: tactile 
changes/ 
unresponsive 
Deployment 
Issue C63013; 
FDA 2906 
Failure to 
Deploy 
C63183; FDA 
1158 
 'Failure of touch 
activation of button' 
could be considered 
as L3. 
  Button over 
responsive 
 Self-
Activation or 
Keying 
C62844; FDA 
1557 
 'Touch activation of 
button leads to 
over-responsiveness' 
could be considered 
as L3 
  Button/keypa
d: tactile 
changes with 
moisture 
 
Environmenta
l Control or 
Utility Issue 
C63209; FDA 
2929 
Moisture or 
Humidity 
Problem 
C62909; FDA 
2986 
Moisture 
Damage 
C62910; 
FDA 1405 
Moisture issue could 
be entered 
separately or 
together as 'failure 
of touch activation 
with observable 
moisture ingress'  
  Blank display 
screen 
Output Issue 
C62941; FDA 
3005 
No Device 
Output 
C62900; FDA 
1435 
No Display 
or Display 
Failure 
C62904; 
FDA 1183 
Likely redundant 
  Failure to 
power up/ 
Failure to 
properly 
shock 
Electrical 
Issue C63007; 
FDA 1198 
Failure to 
Shock or 
Properly 
Shock 
C63158; FDA 
1573 
Failure to 
Discharge 
C63181; 
FDA 1169 
Likely redundant 
 Failure to 
separate 
(1003) 
Unfolding 
issue 
Deployment 
Issue C63013; 
FDA 2906 
Failure to 
Separate 
C63159; FDA 
2547 
 'failure to unfold' 
could be considered 
as L3 
Connection 
or Fitting 
(1300) 
Loose or 
intermittent 
connection 
(1305) 
Intermittent 
power 
Connection 
Issue C62952; 
FDA 2900 
Decoupling 
C63256; FDA 
1145 
 'Loose connection 
with intermittent 
power' could be 
considered 
   Device 
Operates 
Differently 
than Expected 
C62955; FDA 
2913 
Decoupling 
Device Stops 
Intermittently 
C62924; FDA 
1599 
  
Electrical/Ele
ctronic (1400) 
Circuit failure 
(1402) 
No power Electrical 
Issue C63007; 
FDA 1198 
Power Source 
Issue C63025; 
FDA 3010 
Failure to 
Power-Up 
C62992; 
FDA 1476 
Likely redundant 
       
  Intermittent 
power 
   'intermittent power' 
may in addition to 
 49 
 
'connection issue' 
(see above) be 
considered as a L3 
under 'power source 
issue' 
  Intermittent 
power with 
moisture 
ingress/intrusi
on 
Moisture or 
Humidity 
Problem 
C62909; FDA 
2986 
Moisture 
Damage 
C62910; FDA 
1405 
 Moisture issue could 
be entered 
separately or 
together 
  No power – 
damage with 
moisture 
ingress 
Electrical 
Issue C63007; 
FDA 1198 
Power Source 
Issue C63025; 
FDA 3010 
Failure to 
Power-Up 
C62992; 
FDA 1476 
No power is likely 
redundant; 
 
   Moisture or 
Humidity 
Problem 
C62909; FDA 
2986 
Moisture 
Damage 
C62910; FDA 
1405 
 Moisture issue could 
be entered 
separately or 
together 
 Device 
sensing issue 
(1403) 
Failed to 
alarm 
occlusion 
Device 
Sensing Issue 
C63238; FDA 
2917 
Failure to 
Sense 
C63160; FDA 
1559 
 Valid L3: 'failure to 
sense and alarm 
occlusion'  
  Loss of signal  Invalid 
Sensing 
C63061; FDA 
2293 
Failure to 
Select Signal 
C63161; 
FDA 1582 
Likely redundant 
 Power source 
issue (1404) 
No power Electrical 
Issue C63007; 
FDA 1198 
Power Source 
Issue C63025; 
FDA 3010 
Failure to 
Power-Up 
C62992; 
FDA 1476 
Likely redundant 
  Intermittent 
power 
   Possibly valid 
  Power- 
damage with 
moisture 
ingress 
Moisture or 
Humidity 
Problem 
C62909; FDA 
2986 
Moisture 
Damage 
C62910; FDA 
1405 
 Moisture issue could 
be entered 
separately 
  Premature 
battery 
depletion/ 
longevity 
Power Source 
Issue C63025; 
FDA 3010 
Battery Issue 
C63030; FDA 
2885 
Premature 
Discharge of 
Battery 
C62864; 
FDA 1057 
Likely redundant 
Implantable 
device failure 
(1600) 
Migration of 
device or 
device 
component 
(1601) 
Implant tilted Mechanical 
Issue C62961; 
FDA 1384 
Unintended 
Movement 
C62814; FDA 
3026 
Migration of 
Device or 
Device 
Component 
C62917; 
FDA 1395 
Possibly valid 
 Osseodisinteg
ration issue 
(1602) 
Loosening of 
implant 
Mechanical 
Issue C62961; 
FDA 1384 
Osseointegrat
ion Issue 
C62886; FDA 
3003 
 Possibly valid: 
osseodisintegration 
with loosening of 
bone-implant 
interconnection 
Incompatibilit
y (1700) 
Patient-device 
incompatibilit
y (1703) 
Loss of 
capture 
Electrical 
Issue C63007; 
FDA 1198 
Capturing 
Issue C63027; 
FDA 2891 
Failure to 
Capture 
C62993; 
Likely redundant 
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FDA 1081 
Infusion/Flow 
(1800) 
Improper flow 
or infusion 
(1802) 
Catheter 
shaft, 
restricted 
flow 
Infusion or 
Flow Issue 
C63075; FDA 
2964 
Improper 
Flow or 
Infusion 
C63110; FDA 
2954 
Restricted 
Flowrate 
C62849; 
FDA 1248 
Likely redundant 
  History/ 
settings issue- 
inaccurate 
delivery  
  Inaccurate 
Delivery 
C63104; 
FDA 2339 
To be entered 
separately: 1) 
delivery issue; 2) 
settings issue 
   Computer 
Software 
Issue C63269; 
FDA 1112 
Application 
Program Issue 
C63305; FDA 
2880 
Programmin
g Issue 
C62839; 
FDA 3014 
 
Material 
(2000) 
Crack (2002) Display 
damaged 
Material 
Integrity Issue 
C62968; FDA 
2978 
Crack C62971; 
FDA 1135 
 See FDA's 
component codes to 
define display being 
cracked 
  Display: 
damage with 
moisture 
ingress  
   Moisture issue could 
be entered 
separately or 
together 
   Moisture or 
Humidity 
Problem 
C62909; FDA 
2986 
Moisture 
Damage 
C62910; FDA 
1405 
  
 Degrade 
(2003) 
Line through 
display 
Output Issue 
C62941; FDA 
3005 
Improper 
Device Output 
C63108; FDA 
2953 
Incorrect 
Display 
C63088; 
FDA 1184 
Possibly valid as 
Level 4 
  Display 
segments 
missing 
   Possibly valid as 
Level 4 
  Display: dim/ 
fading/ colour 
spectrum 
   Possibly valid as 
Level 4 
  Display: blank 
screen 
 No Device 
Output 
C62900; FDA 
1435 
No Display 
or Display 
Failure 
C62904; 
FDA 1183 
Likely redundant 
  Display cloudy  Improper 
Device Output 
C63108; FDA 
2953 
Incorrect 
Display 
C63088; 
FDA 1184 
Possibly valid as 
Level 4 
  Display: 
scratched 
Material 
Integrity Issue 
C62968; FDA 
2978 
Material 
Deformation 
C63248; FDA 
2976 
Scratched 
Material 
C62846; 
FDA 3020 
Likely redundant; 
'Parts & 
Components' specify 
affected component 
 Material 
discoloured 
(2004) 
Display: dim/ 
fading/ colour 
spectrum 
Output Issue 
C62941; FDA 
3005 
Improper 
Device Output 
C63108; FDA 
2953 
Incorrect 
Display 
C63088; 
FDA 1184 
Possibly valid as 
Level 4 
  Display:    Possibly valid as 
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inkspot Level 4 
 Material 
fragmentation 
(2005) 
Display 
segment 
missing 
   Possibly valid as 
Level 4 
Output issue 
(2400) 
Incorrect or 
inadequate 
result (2402) 
History 
settings issue 
 Incorrect or 
Inadequate 
Result 
C62848; FDA 
1535 
 To be entered 
separately: 1) 
incorrect result; 2) 
settings issue (= 
programming issue) 
   Computer 
Software 
Issue C63269; 
FDA 1112 
Application 
Program Issue 
C63305; FDA 
2880 
Programmin
g Issue 
C62839; 
FDA 3014 
 
  Time and date 
issue 
Computer 
Software 
Issue C63269; 
FDA 1112 
Date-related 
software issue 
C67508; FDA 
2582 
  
  Call service 
alarm issue 
Protective 
Measure Issue 
C62932; FDA 
3015 
Device Alarm 
System Issue 
C63033; FDA 
1012 
False Alarm 
C63152; 
FDA 1013 
Possibly valid as 
Level 4 
  Audio tone/ 
vibration 
issue (no 
sound; weak 
or 
intermittent 
vibration) 
Mechanical 
Issue C62961; 
FDA 1384 
Noise, Audible 
C99179; FDA 
3273 
 Likely redundant 
    Unintended 
Movement 
C62814; FDA 
3026 
Vibration 
C62806; 
FDA 1674 
Likely redundant 
Protective 
(2600) 
Device alarm 
system (2601) 
Audio tone/ 
vibration 
issue (no 
sound; weak 
or 
intermittent 
vibration) 
Protective 
Measure Issue 
C62932; FDA 
3015 
Device Alarm 
System Issue 
C63033; FDA 
1012 
Improper 
Alarm 
C63112; 
FDA 2951 
Audio issue: 
redundant, see level 
4: 
Not Audible Alarm 
C63310; FDA 1019; 
Vibration issue could 
be new L4 
  Frequent/ 
persistent 
occlusion 
   To be filled in 
separately: 
redundant 
   Improper 
Flow or 
Infusion 
C63110; FDA 
2954 
Obstruction 
within Device 
C62897; FDA 
2423 
Occlusion 
within 
Device 
C62896; 
FDA 1423 
 
Temperature 
(2700) 
Overheat of 
device or 
device 
component 
(2705) 
Temperature- 
physical 
damage 
Temperature 
Issue C62922; 
FDA 3022 
Overheating 
of Device or 
Device 
Component 
C62883; FDA 
1437 
 Possibly valid L3 
term: overheating 
with physical 
damage 
  Temperature- 
no physical 
damage 
   Possibly valid L3 
term: overheating 
with no physical 
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damage 
Unintended 
function 
(2800) 
Failure to 
adhere or 
bond (2802) 
Implant-
implant fit: 
cement-
implant non 
bonding 
Device 
Operates 
Differently 
than Expected 
C62955; FDA 
2913 
Failure to 
adhere or 
bond C63032; 
FDA 1031 
 Possibly valid: 
Cement-implant 
non-bonding 
Use error 
(2900) 
Device 
inoperable 
(2906) 
Device 
displays error 
message 
Device 
Operates 
Differently 
than Expected 
C62955; FDA 
2913 
Device 
displays error 
message 
C63205; FDA 
2591 
 Likely redundant 
 
Table 21. Evaluation terms proposed by manufacturers and considered to be valid (when compared to ISO/TS 
19218-1), which were subsequently compared to FDA's device issue terms and evaluated for consideration for 
use in a future globally used nomenclature. Cells with identical/ similar terms are shaded. 
 
Pilot Comparison with FDA's terms  
Level 1 Level 2 Proposed  
level 3 
Level 1 Level 2 Level 3 Comment 
26000, 
Human 
factors 
26009, 
Patient 
anatomy/ 
physiology 
Non-optimal 
orientation of 
implant 
Human 
Factors Issue - 
C91874 19 
Device 
Incorrectly 
Prepared For 
Use Or 
Modified - 
C91876 14 
 Possibly valid as L3 
 26014, Use 
error 
     
26600, 
Materials, 
chemistry 
26604, 
Reactivity 
problem 
Discrepant reaction 
likely due to weak 
antibody and/or 
sample preparation 
MATERIALS 
AND 
CHEMISTRY 
PROBLEM 
C92078; FDA 
174 
REACTIVITY 
PROBLEM 
C92103; FDA 
3231 
 Possibly valid: weak 
antibody reactivity 
And to be entered 
separately: sample 
preparation 
interference 
26700, 
Mechanic
al 
26701, 
Component 
malfunction 
Vibration motor 
alignment 
MECHANICAL 
PROBLEM 
C92079; FDA 
180 
STRESS 
PROBLEM 
C92120; FDA 
3243 
VIBRATION 
PROBLEM 
C92129; 
FDA 649 
Likely redundant 
 26702, 
Fatigue 
Cold/cracked Solder 
on Piezo 
  FATIGUE 
PROBLEM 
C92053; 
FDA 3251 
Likely redundant as 
to be used with 
component: 'solder 
joint' 
 26703, 
Fracture 
battery 
compartment 
cracked 
  FRACTURE 
PROBLEM 
C92055; 
FDA 3252 
Likely redundant & 
to be used with 
component part 
  Bolus button cover 
detached/missing 
   Possibly valid but to 
be categorised 
elsewhere as 
'missing device 
component' 
 26704, 
Leakage/ 
Moisture in pump ENVIRONMEN
T PROBLEM 
IMPROPER 
HUMIDITY 
 Likely redundant; 
Pump to be specified 
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seal C92051; FDA 
331 
C92061; FDA 
332 
under components 
26800,  
No 
medical 
device 
problem 
or failure 
detected 
26801,  
No medical 
device 
problem 
No defect found (on 
testing); No device 
problem 
determined; 
Undetermined: no 
product problem 
identified; 
complaint not 
duplicated;  
Not able to 
reproduce issue 
Unable To 
Confirm 
Complaint - 
C91894 67 
No Failure 
Detected, 
Device 
Operated 
Within 
Specification - 
C91890 71 
 Likely redundant 
 26802, no 
medical 
device 
failure 
detected 
Device not 
returned; Device 
not returned for 
investigation; No 
device returned for 
investigation;  
Product not 
returned; No results 
Available Since No 
Evaluation 
Performed; no 
sample 
 Device Not 
Returned - 
C91883 92 
 Likely redundant 
  Undetermined: 
insufficient info; 
Unable to 
investigate; Not 
confirmed 
   Unclear; Likely 
redundant  
  No fault found on 
testing; no defect 
found; unable to 
reproduce during 
investigation; 
Undetermined : No 
Product Problem 
Identified; no 
systematic failure of 
product or analyser 
to perform as 
intended; 
Undetermined: No 
Product Problem 
Identified 
 No Failure 
Detected, 
Device 
Operated 
Within 
Specification - 
C91890 71 
  Likely redundant 
  Unable to 
adequately 
investigate due to 
an unrelated failure 
   Possibly valid 
29000, 
Unidentifi
ed 
29001, 
Unidentified 
Sample not 
returned; Device 
not returned - no 
evaluation could be 
performed 
 Device Not 
Returned - 
C91883 92 
 Likely redundant 
  Unable to 
reproduce during 
Investigation; 
Device is tested for 
functionality and 
pass; Unable to 
confirm or 
duplicate the 
complaint during 
investigation 
 No Failure 
Detected, 
Device 
Operated 
Within 
Specification - 
C91890 71 
 Likely redundant 
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Table 22. EDMA's event-type and evaluation terms used in the pilot and compared to FDA's device issue 
terms for consideration for use in a future globally used nomenclature. Cells with identical/ similar terms are 
shaded. 
 
Pilot Comparison with FDA's terms Comment 
Level 1 Level 2 Level 1 Level 2 Level 3 Level 4  
Output 
issue 
(2400) 
Discrepant 
negative (2406) 
Output Issue 
C62941; FDA 3005 
Incorrect or 
Inadequate 
Result 
C62848; FDA 
1535 
False Negative 
Result C63149; 
FDA 1225 
 Likely 
redundant 
 Discrepant 
positive (2404) 
  False Positive 
Result C63147; 
FDA 1227 
 Likely 
redundant 
 Discrepant high 
(2405) 
  High Readings 
C63123; FDA 
2459 
 Likely 
redundant 
    Incorrect or 
Inadequate 
Test Results 
C62829; FDA 
2456 
High Test 
Results 
C63122; 
FDA 2457 
Likely 
redundant 
 Reproducibility 
issue: Non-
reproducible 
result (2408) 
  False Reading 
from Device 
Noncompliance 
C63145; FDA 
1228 
 Possibly 
redundant; 
needs to be 
further 
explored 
Operator 
issue 
(3000) 
Splash (3001) Use of Device 
Issue C63318; FDA 
1670 
Device 
Handling Issue 
C95879; FDA 
3265 
  Needs to be 
further 
explored 
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5 Conclusions 
 
The submitted MIR pilot forms represent only a subset of all device categories 
(based on e.g. FDA classification panels or GMDN categories), and as such do not cover 
the entire spectrum of devices present on the market. This is due to the design of the 
pilot where (1) Competent Authorities suggested a focused participation of companies in 
specific sectors, and (2) manufacturer participation was voluntary. This potential data 
bias needs to be considered when interpreting the results of the pilot and in any 
nomenclature development that results from the pilot. Additional bias may come from 
the observations that (1) no SMEs participated in the pilot, and (2) a single 
manufacturer has submitted > 60% of the total number of forms. This has also led to 
the over-representation of one of the device categories with >70% of the total number 
of pilot forms.  
Important lessons have been learned from the pilot relating to the design of the 
reporting form. If there is the intention to allow proposals of new terms in the context 
of incident reporting templates, this should concern all levels and be implemented in 
a user-friendly manner, which was not the case with the MIR pilot form. The pilot 
results showed that the majority of new terms proposed concern level three terms. We 
suspect that this was due to the fact that it was technically rather difficult to propose 
new level 1 or level 2 terms. Additionally, the analysis showed that not more than three 
choices per level appear to be needed to describe the majority of incidents or final 
investigation. 
An analysis of the terms and definitions used in the pilot showed that the ISO/TS 
19218 terms are not fully adequate, and though EDMA has proposed new terms to 
complement these terms, the definitions accompanying EDMA's new terms would 
need revision: four level 2 codes (#2404→2407) concerning discrepant results (i.e. 
discrepant positive, high, negative, low) have identical definitions ('Issue associated with 
end results provided by the device'). 
Even on a relatively small scale study as the one analysed here (741 eligible submissions 
from manufacturers), it is clear that the ISO/TS 19218 terms show severe drawbacks 
that lead us to conclude that the terminology, in its present state, is inadequate for 
purposes of medical device problem and evaluation reporting. The JRC has proposed 
modifications of and additions to ISO/TS 19218 terms to resolve the most 
frequently encountered nomenclature issues that have been proposed by manufacturers. 
These proposals, however, are not only applicable to ISO but will inform nomenclature 
development on international level through the IMDRF's Adverse Event Working Group. 
For evaluation terms, they relate primarily to the level 1 term 26800, 'No medical device 
problem or failure detected'. By making a clear distinction on whether an investigation 
took place or not, it is possible to regroup commonly proposed terms and represent 
them with a single term. It is noteworthy that ISO appears to have abolished the 
relevant terms when composing their terminology based on that of US FDA since the 
latter makes this crucial and highly informative distinction. 
This final report provides some insight into the nomenclature proposed by 
manufacturers. The number of newly proposed terms has surpassed expectations. 
However, some reporters of incidents using the MIR pilot form did apparently have 
insufficient knowledge of the ISO/TS 19218 terms or incomplete understanding 
of the subsections of the form. Common flaws were the proposal of redundant terms 
(at all levels) or the reporting of 'patient outcome' terms for purposes of describing 
device problems ('event-type' terms). Some of the confusion may stem from the rather 
unfortunate name that ISO chose for the nomenclature for medical device problem 
reporting ('adverse event type') which appear to suggest that also adversity (i.e. at 
patient level) is reported with this nomenclature, which is however not the case. It is 
also possible that a more elaborate nomenclature needs to be developed for 
certain device categories like for orthopaedic devices. 
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Finally, we have compared the proposed terms to those contained in the FDA 
terminology on medical device issues since the latter serves as a basis for the 
development of internationally harmonised nomenclature of medical device problems in 
the context of IMDRF's Adverse Event Working Group. Our analysis will feed into the 
work of this group.  
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6 Annex 1 
 
This annex contains three parts: 
 Part 1 outlines, on the basis of parts 2 and 3, key recommendations for future 
work towards effective tools of incident reporting by manufacturers in the EU. 
 
 Part 2 highlights the key agreements reached during the workshop ('Developing a 
roadmap for the integrated MIR form') hosted by COCIR in Brussels on the 3rd of 
February 2016, as well as some open issues that remain to be addressed in 
future work. 
 
 Part 3 summarises the proposals raised in communications made thereafter, 
including at the MDEG Vigilance meeting (Brussels) on the 8th and 9th of March 
2016, as well as via emails and teleconferences. 
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6.1 Recommendations 
 
JRC summarises the following key recommendations for future work towards developing 
effective tools of incident reporting by manufacturers in the EU: 
 
1) Towards an integrated MIR form and recommendations for future electronic 
reporting tools (e.g. EUDAMED) 
 
To enhance the effectiveness and usefulness of manufacturer incident reporting, it 
is now important to develop a new MIR form that combines the existing one (narrative 
text) with reporting tools assessed during the pilot, i.e. nomenclatures, similar incidents, 
etc. A working group composed of regulators and stakeholders and the European 
Commission should develop this integrated MEDDEV MIR form and, in addition, develop 
recommendations for the design of the future MDR EUDAMED reporting template. The 
group should operate in the context of the MDEG vigilance group. 
As a first step, terms of reference should be drafted to frame the group's work in a 
transparent manner, e.g. (1) mandate & scope, (2) composition, (3) deliverables, and 
(4) timelines. Ideally the integrated MEDDEV MIR should be issued in late 2016 or early 
2017. The form should remain stable for the next years until the future MDR EUDAMED 
is fully functional. Manufacturers shall be encouraged to implement the new form in a 
timely manner. 
 
2) Use of IMDRF nomenclature as a mandatory reporting requirement 
 
In order to reduce the burden for industry with respect to different reporting 
"languages", the EU should commit to globally applicable nomenclatures currently 
developed by IMDRF with participation of EU experts. In the summer of 2016, the 
relevant IMDRF working group has finalised the first element of the Adverse Event 
Terminology on medical device problems. It is expected that, following endorsement by 
the IMDRF management committee, this nomenclature could become available in Q1 
2017 – free of charge. Moreover, commitment to a globally applicable nomenclature will 
have substantial benefits for competent authorities and health practitioners (reduction of 
ambiguity, exchange of data) with ensuing benefits for patients.  
Thus, the new MIR form should foresee four dedicated placeholders for the 
upcoming IMDRF terminologies. While the form would be implemented only once, the 
terminologies would be populated and activated as they become available. The 
nomenclatures will be: (1) Medical device problem; (2) Patient problem; (3) Cause 
investigation; and (4) Components.  
Consequently, the ISO/TS 19218 nomenclatures should not be used for reporting 
in the EU. This report shows that the nomenclatures are not fully adequate and that the 
rate of updates is insufficient in view of the pace of innovation in the medical technology 
field.  
IMDRF is already considering effective ways of maintaining regulatory 
nomenclatures drawing on possible proposals from competent authorities, industry 
associations and health practitioners. 
 
3) Voluntary use of in-house terms by manufacturers 
 
In addition to the mandatory use of IMDRF terms, manufacturers should be 
encouraged to provide in the future integrated MIR form and on a voluntary basis, in-
house terms. Use of in-house terms could be helpful for describing the actual incident as 
well as for describing similar incidents that have occurred. 
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6.2 Workshop agreements and open issues 
 
6.2.1 Workshop agreements 
 
This section highlights the key agreements reached during the workshop 'Developing a 
roadmap for the integrated MIR form' organised by the European Commission (DG 
GROW, DG JRC) and MHRA, and hosted by COCIR in Brussels on 3 February 2016. 
 
1. Finalisation of the pilot: To end the pilot as from the workshop date, being 3 
February, 2016.  
2. Development of a new integrated MIR form: To further develop the new 
MEDDEV MIR form, which in essence would integrate the MIR pilot form with the 
current MEDDEV MIR form. More specifically, it would: 
o complement the sections requesting narrative descriptions on 'Incident 
information' and 'Results of the manufacturer's final investigation' with sections 
for the mandatory reporting of adequate terms and codes (see point 3);  
o include the provision of data for all similar incidents. 
3. Use of IMDRF nomenclatures in the integrated MIR form: To incorporate as 
nomenclatures, the one currently being developed by IMDRF, specifically because it 
is being developed for use at a global level, and because the ISO/TS 19218 
nomenclature, which was used in the MIR form pilot, proved to be inadequate. 
Additional drawbacks to ISO/TS 19218 include that it is not being updated regularly 
and not being compliant with the new regulation in terms of being freely available.  
4. Introduce placeholders for nomenclatures whilst these are under 
development: To introduce placeholders in the new MEDDEV MIR form for the 
future IMDRF terms/codes. Four placeholders will need to be foreseen as four sets of 
nomenclature will be developed that relate to (1) medical device problems; (2) 
patient problems; (3) cause investigation; and (4) components of the device, which 
are affected. The first set on medical device problems is expected to be issued by 
IMDRF in March 2017. 
5. Mandatory use of future regulatory IMDRF nomenclatures: To stipulate the use 
of nomenclatures for adverse event reporting as a mandatory requirement. 
6. Voluntary use of in-house data for additional purposes: To encourage 
manufacturers to use their in-house terms in the dedicated space for the provision of 
similar incident data.  
 
 
6.2.2 Open issues identified during the workshop 
 
The major open issues identified during the workshop include: 
 
1. Incidents involving more than one device: To consider adaptations to the future 
MIR template in view of enabling the reporting of incidents involving more than one 
device, or one device but in combination with a reagent(s) (for IVDs). 
2. Incidents involving more than one event: To resolve the procedure to report the 
same incident with multiple events using the pdf-based MIR form. An additional issue 
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to tackle is whether the first event described should be the most serious one to 
consider or not. 
3. Similar incident - reporting periods: To define the time periods for reporting 
similar incidents. Should the time period be device-dependent? Consider the case of 
implants being present in the body for extended periods of time: should survivorship 
curves be included as an incident can happen any time during the lifespan of the 
device? To clarify how similar incident data are calculated, particularly in the case 
when more than one event or evaluation term is provided, e.g. when more than one 
issue has occurred in the same event.  
4. Reporting of sales data for use as denominator data:  To further discuss the 
reporting of denominator data (i.e. number of devices on the market). While it 
appears clear that denominator data need to be based on cumulative sampling of 
devices sold (sales data) over a given period or several periods, it is precisely the 
number and duration of these periods that needs to be defined. Further, it needs to 
be considered whether the requirements for provision of sales data should be 
differentiated based on the type of device: consider for instance the case of implants, 
their sales data and the active installed base number (including the difficulties in 
determining the latter). 
5. Reporting investigations - causes versus suspected causes: Further 
discussions are needed to resolve issues concerning the reporting of investigations 
into the causes of given incidents. For instance, the form should distinguish between 
causes identified as a result of an investigation of the device (or the relevant batch) 
versus 'suspected causes' that are not fully evidence-based but derived from 
plausibility reasoning. 
6. IVD-specific issues: Specifically, for IVD medical devices: to foresee (1) sufficient 
terms within the nomenclature for incident reporting, and (2) sufficient space to 
enter terms not only for the device but also the reagent. For the latter case: is the 
reporting procedure and method for searching similar incidents clear?  
7. To encourage manufacturers to provide more complete and consistent reports, as 
requested by competent authorities. 
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6.3 Post-workshop proposals and concerns 
 
6.3.1 Post-workshop proposals 
 
1. Setting up a Working Group for developing the integrated MIR form & 
framing proposals for the EUDAMED reporting template: To set-up a working 
group chaired by MHRA and DG JRC to further develop the new MEDDEV MIR pdf 
form. The group will include experts from competent authorities and stakeholders 
(e.g. industry) and will operate in the context of the MDEG Vigilance Working Group. 
The group will also develop proposals for the future reporting template of the MDR 
EUDAMED database, which in contrast to the current pdf form will be web-based. The 
recommendations of the working group can be taken up by the EUDAMED Steering 
Committee and the EUDAMED Working Group on the electronic vigilance/market 
surveillance modules. 
2. Implementation of the integrated MIR form: To implement the new integrated 
MEDDEV MIR form with placeholders for the future IMDRF nomenclature in Q4 2016/ 
Q1 2017. This would in effect be a one-time implementation and should remain 
stable for the next four years until the future MDR EUDAMED is activated, thereby 
promoting optimal resource use. As soon as the IMDRF nomenclatures will become 
available (in a sequential manner), they can be implemented as modules of the form. 
The form however would be implemented only once. 
3. Timely implementation of nomenclature: To encourage manufacturers to timely 
implement the new nomenclature in their incident reporting systems. 
4. Follow-up on new Regulation: To follow up on any new developments in the 
upcoming regulation relevant for incident reporting using the MIR form or the future 
EUDAMED system. 
 
 
6.3.2 Post-workshop identification of open issues 
 
The major post-workshop discussions have identified the following open issues: 
 
1. There was a proposal to continue using with the ISO/TS 19218 nomenclature in the 
new MEDDEV MIR form until IMDRF terms become available. This was contentiously 
discussed. A key drawback identified relates to the potential disproportionate cost of 
implementing such a short term activity by manufacturers. 
2. To reduce the time foreseen by manufacturers (6 to 12 months or more requested) 
for the implementation of new nomenclature in their automated incident reporting 
systems.  
3. To speed up the development of IMDRF's nomenclature. This could be done via a 
'push' involving activities by the European members. Such a push could, however, 
come at the cost of a suboptimal nomenclature being developed and requiring a 
more extensive maintenance of the nomenclature in the future. 
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